1 
 PILOT CLINICAL TRIAL FOR THE EVALUATION OF TRANSCRANIAL ALTERNATING 
CURRENT STIMULATION FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER  
IRB # 14 -1622  
 
NCT0233928 5 
 
Funding Mechanism:  National Alliance for Research on Schizophrenia and Depression 
(NARSAD) - The Brain and  Behavior Research Foundation  
Principal Investigator: Dr. Flavio Frohlich, PhD   
Co-Investigator: Dr. David Rubinow, MD  
Draft or Version Number: 5.0 
04 January  2016 
 
 
 
 
2 
 STATEMENT OF COMPLIA NCE  
The study will be carried out in accordance with Good Clinical  Practice (GCP) as required by the 
following  
 United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45  CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312 ) 
 ICH E6; 62 Federal Register 25691 (May 9, 1997)  
All key  personnel (all individuals responsible for the design and conduct of this study) have 
completed Human Participant s Protection and HIPA A Training.  
3 
 SIGNATURE PAGE  
The signature below constitutes the approval of this protocol and the attachments, and provid es 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal regulations and ICH guidelines.  
 
Signed:   
Date:   
 
 
   
4 
 TABLE OF CONTENTS  
 Page  
Statement of Compliance  ................................ ................................ ................................ ................. 2 
Signature Page  ................................ ................................ ................................ ................................ .3 
Table of Contents  ................................ ................................ ................................ ............................. 4 
List of Abbreviations  ................................ ................................ ................................ ....................... 7 
Protocol Summary  ................................ ................................ ................................ ........................... 9 
1 Key Roles  ................................ ................................ ................................ .............................. 13 
2 Introduction: Background Information and Scientific Rationale  ................................ .......... 15 
2.1 Background Information  ................................ ................................ ........................... 15 
2.2 Rationale  ................................ ................................ ................................ ................... 15 
2.3 Potential Risks and Benefits  ................................ ................................ ..................... 16 
2.3.1  Potential Risks  ................................ ................................ .............................. 16 
2.3.2  Known Potential Benefits  ................................ ................................ ............. 17 
3 Objectives  ................................ ................................ ................................ ............................. 19 
3.1 Study Objectives  ................................ ................................ ................................ .......19 
3.2 Study Outcome Measures  ................................ ................................ ......................... 19 
3.2.1  Primary Outcome Measures  ................................ ................................ .......... 19 
3.2.2  Secondary Outcome Measures  ................................ ................................ ......19 
4 Study Design  ................................ ................................ ................................ ......................... 20 
5 Study Enrollment and Withdrawal ................................ ................................ ........................ 21 
5.1 Participant Inclusion Criteria  ................................ ................................ .................... 21 
5.2 Participant Exclusion Criteria  ................................ ................................ ................... 21 
5.3 Strategies for Recruitment and Retention  ................................ ................................ .22 
5.4 Treatment Assignment Procedures  ................................ ................................ ........... 23 
5.4.1  Rand omization Procedures  ................................ ................................ ........... 23 
5.4.2  Reasons for Withdrawal  ................................ ................................ ................ 23 
5.4.3  Handling of Withdrawals  ................................ ................................ .............. 23 
5.4.4  Termination of Study  ................................ ................................ .................... 24 
6 Study Intervention/Investigational Product  ................................ ................................ .......... 25 
6.1 Study Product Description  ................................ ................................ ........................ 25 
6.1.1  Device Description ................................ ................................ ....................... 25 
6.1.2  Operation ................................ ................................ ................................ .......26 
6.1.3  Safety Percautions  ................................ ................................ ......................... 27 
6.2 Preparation and Administration of Study Investigational Product  ........................... 28 
6.3 Assessment of Participant Compliance with Study Investigational Product  ............ 29 
7 Study Schedule ................................ ................................ ................................ ...................... 30 
7.1 Screening ................................ ................................ ................................ ................... 30 
5 
 7.2 Enrollment/Baseline  ................................ ................................ ................................ ..31 
7.3 Stimulation Sessio ns ................................ ................................ ................................ .31 
7.4 Follow -up ................................ ................................ ................................ .................. 33 
7.5 Final Study Visit  ................................ ................................ ................................ .......33 
8 Study Procedures/Evaluations  ................................ ................................ .............................. 34 
8.1 Clinical Evaluations  ................................ ................................ ................................ ..34 
8.2 Laboratory Evaluations  ................................ ................................ ............................. 35 
8.2.1  Clinical Laboratory Evaluations  ................................ ................................ ...35 
8.2.2  Special Assays or Procedures  ................................ ................................ .......36 
9 Assessment of Safety  ................................ ................................ ................................ ............ 37 
9.1 Specifi cation of Safety Parameters  ................................ ................................ ........... 37 
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  ................................ ................................ ................................ ................. 37 
9.2.1  Adverse Events  ................................ ................................ ............................. 37 
9.2.2  Expected Adverse Reactions ................................ ................................ ......... 39 
9.2.3  Serious Adverse Events  ................................ ................................ ................ 39 
9.2.4  Unanticipated Problems  ................................ ................................ ................ 40 
9.3 Reporting Pro cedures  ................................ ................................ ................................ 40 
9.3.1  Reporting of Pregnancy  ................................ ................................ ................ 41 
9.4 Type and Duration of Follow -up of Participants after Adverse Events  .................... 41 
9.5 Halting Rules  ................................ ................................ ................................ ............ 41 
9.6 Safety Oversight ................................ ................................ ................................ ........ 42 
10 Clinical Monitoring  ................................ ................................ ................................ ............... 43 
10.1 Frohlich Lab Monitoring Plan  ................................ ................................ .................. 43 
11 Statistical Considerations  ................................ ................................ ................................ ......44 
11.1 Study Hypotheses ................................ ................................ ................................ ......44 
11.1.1 Primary Objective………………………………………………….............. 44 
11.1.2 Secondary Objective……………………………………………….............. 44 
11.2 Sample Size Considerations  ................................ ................................ ...................... 44 
11.3 Final Analysis Plan  ................................ ................................ ................................ ...44 
12 Source Documents and Access to Source Dat a/Documents  ................................ ................. 45 
13 Ethics/Protection of Human Participants  ................................ ................................ .............. 47 
13.1 Ethical Standard  ................................ ................................ ................................ ........ 47 
13.2 Institutional Review Board  ................................ ................................ ....................... 47 
13.3 Informed Consent Process  ................................ ................................ ........................ 48 
13.4 Exclusion of Women, Minorities, and Children (Special Populations)  .................... 48 
13.5 Participant Confidenti ality ................................ ................................ ........................ 49 
13.6 Study Discontinuation  ................................ ................................ ............................... 49 
14 Data Handling and Record Keeping  ................................ ................................ ..................... 50 
14.1 Data Management Responsibilities ................................ ................................ ........... 50 
14.2 Data Capture Methods  ................................ ................................ .............................. 50 
6 
 14.3 Types of Data  ................................ ................................ ................................ ............ 50 
14.4 Timing/Reports  ................................ ................................ ................................ ......... 51 
14.5 Study Records Retention ................................ ................................ ........................... 51 
14.6 Protocol Deviations  ................................ ................................ ................................ ...52 
15 Publication Policy  ................................ ................................ ................................ ................. 53 
16 Literature References  ................................ ................................ ................................ ............ 54 
Supplements/Appendices  ................................ ................................ ................................ ............... 57 
Appendix A : Schedule of Events  ................................ ................................ ................................ .....57 
Appendix B: Study Start Up Checklist   ................................ ................................ .......  .................. 58 
Appendix C : Documentation of Informed C onsent Process  ................................ ........   .................. 59 
Appendix D: Consent Amendment T racking Log  ................................ ........................   .................. 61 
Appendix E: Informed Consent Evaluation Feedback . ................................ ...............   .................. 62 
Appendix F: IRB Amendment Tracking Log  ................................ ...............................   .................. 63 
Appendix G: Note to File  ................................ ................................ ............................   .................. 64 
Appendix H: Inclusion/Exclusion Criteria Checklist with signature of PI for participant 
eligibility.  ................................ ................................ ................................ ....................   .................. 65 
Appendix I: Telephone Co ntact Log  ................................ ................................ ...........   .................. 66 
Appendix J: Adverse Event Tracking Log  ................................ ................................ ..  .................. 67 
Appendix K: Unexpected/Serious Adverse Event  Tracking Log ................................ .  .................. 68 
Appendix L: Adverse Event Repor t Form  ................................ ................................ ...  .................. 69 
Appendix M: Serious Adverse Event Report Form  ................................ .....................   .................. 71 
Appendix N: Delegation of Authority Log  ................................ ................................ .  .................. 75 
Appendix O: Protocol Deviation  ................................ ................................ ................   .................. 76 
Appendix Q: Enrollment Log  ................................ ................................ ......................   .................. 77 
Appendix R: Training Log  ................................ ................................ .........................   .................. 78 
Appendix S: Participant Off Study  ................................ ................................ ..............   .................. 79 
Appendix T: Telephone Recruitmen t Script  ................................ ................................   .................. 81 
 
 
 
 
 
 
 
 
7 
  
 
LIST OF ABBREVIATION S 
AE Adverse Event  
ANOVA  Analysis of Variance  
BDI Beck Depression Inventory  
CAPA  Corrective and Preventative Action  
CFR  Code of Federal Regulations  
CGI Clinical Global Interview  
CNS  Central Nervous System  
Co-I Co-Investigator  
CRF  Case Report Form  
CRMS  Clinical Research Management System  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
dl-PFC Dorso-lateral  Prefrontal Cortex  
DMV  Department of Motor Vehicles  
DSM -IV Diagnostic and Statistical Manua l of Mental Disorders (Version IV)  
DSMB  Data and Safety Monitoring B oard 
eCRF  Electronic Case Report Form  
EEG  Electroencephalogram  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HDRS17  Hamilton Depression Rating Scale (17 item)  
HIPAA  Health Insurance Portability and Accountability Act  
HSD  Honest Signif icant Difference  
Hz Hertz  
ICF Informed Consent Form  
IDE Investigational Device Exemption  
IRB Institutional Review Board  
JAMA  Journal of t he American Medical Association  
LAR  Legally Authorized Representative  
MADRS  Montgomery -Asberg Depression Ratin g Scale  
MDD  Major Depressive Disorder  
MINI  Mini International Neuropsychiatric Interview  
MOCA  Montreal Cognitive Assessment  
NAMI  National Alliance on Mental Illness  
NARSAD  National Alliance for Research on Schizophrenia and Depression   
NIH National I nstitutes of Health  
NIMH  National Institute of Mental Health  
8 
 NRB  Neurosciences Research Building  
OHRE  Office of Human Research Ethics  
OHRP  Office for Human Research Protections  
PI Principal Investigator  
SAE  Serious Adverse Event/Serious Adverse Expe rience  
SB Suicidal Behavior  
SI  Suicidal Ideation  
SMC  Safety Monitoring Committee  
SPI Serial Peripheral Interface  
SOP Standard Operating Procedure  
tACS  Transcranial Alternating Current Stimulation  
tDCS  Transcranial Direct Current Stimulation  
TMS  Transcranial Magnetic Stimulation  
UE Unexpected Event  
UNC  University of North Carolina  
UNC -CH University of North Carolina at Chapel Hill  
US United States  
YMRS  Young Mania Rating Scale  
9 
 PROTOCOL SUMMARY  
 
Title:  Pilot Clinical Trial for the Evaluation  of Transcranial Alternating 
Current Stimulation for the Treatment of Major Depressive 
Disorder  
Précis:   
The purpose of this clinical trial is to investigate the effects of 
non-invasive transcranial alternating current stimulati on (tACS) 
on patients who s uffer from Major Depressive Disorder (MDD). 
We will recruit 60 males and females with unipolar, non -
psychotic MDD.  Eligible participants will have 5 daily (one 
week Monday through Friday), 40 minute stimulation sessions. 
Parti cipants will be randomly assi gned to one of three groups; 
sham stimulation, 10 Hz (alpha) tACS or 40 Hz (gamma) tACS. 
Participation will include 1 to 8 visits. At the initial session , 
consent will be given and eligibility will be determined. Eligible 
partic ipants will undergo  5 daily stimulation sessions (40 
minutes duration) with daily assessment of suicide risk , mania , 
and stimulation side -effects . Clinical assessments will be 
performed at baseline, 5th day of stimulation, the 2 week follow -
up and the 4 week follow -up using the Montg omery -Asberg 
Depression Rating S cale (Attachment 8) . Neurophysiological 
(EEG) and cognitive assays will be performed before and after 
stimulation. Please see Appendix A for a detailed schematic 
describing all visits and assessments.  
 
Objectives:  
 Our prim ary objective is to conduct a pilot clinical trial to 
establish the feasibility and collect first effectiveness data for the  
treatment of patients with MDD  with tACS . The treatment 
rationale is  to down -regulate pathological alpha oscillations in 
left dl -PFC of unmedicated patients with MDD . The primary 
outcome measure of this study is the change in Montgomery -
Asberg Depression Rating Scale  (MADRS) between initial 
assessment and assessment at the 4 week follow -up. In addition, 
we will also assess th e change in MADRS between week 2 and 
week 5 .Changes in alpha power between the first and the last day 
of stimulation is the secondary outcome of this study.  In 
addition, we will perform explorative analysis of the EEG data 
10 
 from all three time points as a pilot stu dy for the future 
development of EEG -based biomarkers.   
 
 
Population:  
 We will recruit 60 males and non -pregnant females ages 18 -65 
with a diagnosis of unipolar, non -psychotic MDD, who have 
been free of medication for the treatment of MDD for at least 6 
months , including antipsychotic and anticonvulsant medications. 
Eligible participants will have a Hamil ton Depression Rating 
Scale > 17 and low suicide risk.  Participants will be recruited 
from the Chapel Hill, Durham and Raleigh areas.  
Phase:  Pilot Study  
Number of Sites:  This is a single site study performed at University of North 
Caroline - Chapel Hill.  
Study Duration:  This study will take 2 years to complete  
Participant Participation 
Duration:  Eligible participants who complete this clinical trial wil l have a 
total of 8 visits; an initial ses sion, 5 days of stimulation, a 2  and a 
4 week follow up visit  (Follow up sessions are measured from 
first day of stimulation) .  The initial s ession will take 
approximately 2 hours, the first and last day of stimu lation will 
take approximately 5  hours. Days 2 through 4 of stimulation will 
take 1 .5 hours each day.  The one  week fol low up will take 
approximately 2  hours and the four  week follow up will take 
approximately 4 hours.  We estimate that total participation  to be  
approximately 22.5 hours.  
Description of Agent or 
Intervention:  We will be using an active sham, 10 Hz and 40 Hz tACS. Active 
sham treatment will include 10 seconds of ramp in to 1 minute of 
10 Hz tACS with a ramp out of 10 seconds for a total of 80 
seconds of stimulation. The choice of an active sham is 
motivated to enhance success of patient blinding by mimicking 
skin sensations associated with tACS.  Both 10 Hz and 40 Hz will 
also have a 10 second ramp in and ramp out with 40 minutes of 
stimulation  for a total of 2420 seconds. Stimulation waveforms 
are sine -waves with a peak -to-peak amplitude of 2 mA.  
Participants will stay in a relaxed yet experimentally controlled 
state by watching a nature movie such as “Reef scape” during 
stimulation.  
11 
  
Estimate d Time to 
Complete Enrollment:   
We estimate that it will take 2 years to complete enrollment of 
participants.  
12 
 
*Schematic of Study Design:  
Table 1. The 60 participants will be randomized into one of three of the following arms 
ARM 1  20 participants  Sham  
ARM 2  20 participants  10 Hz tACS  
ARM 3  20 participants  40 Hz tACS  
  
 
 
*Weeks are based on time from initial stimulation session  
 
13 
 1 KEY ROLES  
Individuals:  Principal Investigator:   Flavio Frohlich, Ph .D. 
 Co-Investigator: David Rubinow M.D.  
Medical Moni tor: Asa Cordle, M.D.  
  
Flavio Frohlich Ph.D. – Principal Investigator     
UNC - Chapel Hill Dep artment of Psychiatry  
Email:  flavio_frohlich@med.unc.edu          
Office:  4109F Neuroscience Research Buildin g 
Phone:  (919) 966 -4584  
 
David Rubinow M.D. – Co-Investigator  
UNC - Chapel Hill Department of Psychiatry    
E-mail:   drubinow@med.unc.edu  
Office:  304 MacNider Hall     
Phone:  (919) 445 -0208  
 
Courtney Lugo MPH . – Project Manager/Study Coordinator  
UNC - Chapel Hill Department of Psychiatry  
E-mail:  courtney_lugo@med.unc.edu     
Office: Medical School Wing C -233 
Phone: (919) 962-5271  
 
Juliann Mellin B.A. – Study Coordinato r 
UNC - Chapel Hill Department of Psychiatry  
E-mail: juliann_mellin@med.unc.edu    
Office: Medical School Wing C -233 
Phone: (919)  966-9929  
 
Morgan Alexander B.S/BA – Study Coordinator  
UNC_ Chapel Hill Depart ment of Psychiatry  
E-Mail: Morgan_Alexander@med.unc.edu   
Office: Medical school Wing C - 233 
Phone: (919) 966 - 5271  
 
Michael Boyle B.S. – Graduate Research Assistant    
UNC - Chapel Hill Department of Biome dical Engineering  
Email: mrboyle@live.unc.edu      
14 
 Office:  4129 Neuroscience Research Building   
Phone: ( 919)-966- 2682    
  
Bradley Vaughn M.D. – Other      
UNC - Chapel Hill Department of Neurology   
  
E-mail: vaughnb@neurology.unc.edu    
Office: 2122 Ph ysician Office Building    
Phone:(919) 966 -8178  
 
Asa Cordle M.D. – Medical Monitor      
UNC - Chape l Hill Department of Psychiatry    
Email: cordle@email.unc.edu     
Office: UNC Hospitals CB#  7160     
Phone: (919) 966 -5217  
 
Institutions:  University of North Carolina - Chapel Hill  
 
Other:  IRB 
University of North Carolina -Chapel Hill  
Medical School Building 52  
Mason Farm Road  
CB #7097  
Chapel Hill, NC 27599 -7097  
(919) 966 -311 
Brain & Behavior Research Foundation  
90 Park Avenue, 16th Floor  
New York, NY 10016  
(646) 681 -4888  
15 
 2 INTRODUCTION: BACK GROUND INFORMATION A ND 
SCIENTIFIC RATIONALE  
2.1 Background Information  
 
Major depressive disord er (MDD) is a common, severe psychiatric illness that is associated with 
pathological dynamics of large -scale neuronal networks.  More effective and safe therapies for 
MDD are desperately needed. Brain research has recently begun to uncover the biological 
substrate of depression: impaired ability of the brain to organize its electric activity into 
meaningful patterns that enable effective information processing.  
 
Patients with MDD exhibit elevated oscillatory activity in left dorso -lateral prefrontal corte x (dl-
PFC) in the alpha (8 -12 Hz) frequency band (Henriques and Davidson, 1990). Alpha oscillations 
represent a fundamental state of neuronal hypoactivity that actively mediates suppression of 
information processing in thalamo -cortical circuits (Laufs et a l., 2003; Palva and Palva, 2007). 
Transcranial magnetic stimulation to treat MDD has been recently approved by the FDA and is 
based on stimulation with a 10 Hz pattern. Importantly, bifrontal stimulation in the alpha 
frequency band with low -amplitude elect ric fields have recently been found to reduce symptoms 
in a multicenter, double -blind, sham -controlled study (personal communication, Dr. Linda 
Carpenter, Brown University). However, it has remained unknown if transcranial alternating 
current stimulation  (tACS) , a safe and non -invasive brain stimulation modality , is also an 
effective modulator of the network dynamics that mediate symptoms of depression. Addressing 
this lack in knowledge is critical for advancing our understanding of the network -level substr ate 
of MDD and for the rational design of novel brain stimulation paradigms that directly target 
pathological network dynamics.  
 
2.2 Rationale  
 
Hypoactivity in the left dorso -lateral prefrontal cortex is a hallmark of MDD (Brunoni et al., 
2010). Increasin g activity levels by transcranial direct current stimulation (tDCS) that utilizes a 
constant current to increase cortical excitability has recently been demonstrated to be effective 
for the treatment of MDD (Brunoni et al., 2013). However, previous studies  were more equivocal 
and recent meta -reviews came to differing conclusions (Berlim et al., 2013; Kalu et al., 2012). 
Our approach aims to use more targeted stimulation that directly modulates oscillatory activity. 
Specifically, we use non -invasive brain st imulation to target pathologically increased levels of 
alpha oscillations in left dl -PFC in depressed patients (e.g. Henriques and Davidson, 1990). 
tACS utilizes sine -wave stimulation waveforms that likely enhance specific oscillations (Ali et 
al., 2013; H errmann et al., 2013). In contrast, suppressing oscillations with tACS , such as for the 
downregulation of pathologically enhanced alpha oscillations , is a more challenging task. The 
proposed work is the first study of its kind to evaluate the feasibility a nd effectiveness of two 
16 
 different tACS -based stimulation paradigms. We will use 10 Hz stimulation motivated by the 
recent success in 10 Hz stimulation for treatment of depression with transcranial magnetic 
stimulation and we will use 40 Hz stimulation in o rder to indirectly modulate alpha oscillations 
due to endogenous antagonistic coupling of alpha and gamma frequency activity.  
 
2.3 Potential Risks and Benefits  
 
2.3.1 Potential Risks  
 
Risk of Confidentiality Breach : In the unlikely event of a breach of confiden tiality, people 
might discover that an individual was involved in this research study. This is especially 
sensitive because the clinical population recruited for this study may be subjected to 
negative consequences caused by the stigma of mental disorders . Furthermore, some 
might not agree with the principle of participating in research or of changing natural brain 
activity. To avoid breaches in confidentiality, study documents that contain personal 
information, including the informed consent document, and the document that links study 
ID number s to personal identifying information are kept in locked filing cabinets in 
locked rooms , separate from any source documents containing participant dummy 
identifiers . All data is stored in locked cabinets inside locke d offices; electronic data will 
be stored only on password -protected computers, and data encryption methods will be 
used during communication between investigators. Only study personnel will have access 
to these data. All study staff participate in annual human participant training that includes 
education about responsibilities to the minimize risk of confidentiality breach.   
 
Risk of Embarrassment : Self -report assessments contain  questions regarding sensitive 
personal information. This risk is necessary in  order to assess mood symptoms and 
associated psychopathology. Participants will be assured upon intake that only study 
personnel will see any clinical rating s.  
 
Risk of Injury and Discomfort : Transcranial current stimulation has been used without 
any rep orts of serious side -effects  for more than a decade . This stimulation mode has 
NOTHING to do with electroconvulsive therapy that applies many orders of magnitude 
higher stimulation current. Rather, transcranial current stimulation is so weak that it does 
not cause  super -threshold activation of neurons (Frohlich and McCormick, 2010). In 
particular, t ACS has been used without reports of any serious side -effects. Some 
participants report a transient mild tingling, burning, or itching underneath the electrodes 
and headache, but no other side effects have been noted. Importantly , it remains unclear 
if these mild side -effects were caused by the transcranial brain stimulation. In order to 
monitor these side -effects, we will be administering an adverse effects stimu lation 
questionnaire (Attachments  6 &7) after each stimulation session to determine whether 
17 
 these effects were experienced. Research personnel present during these sessions will 
also check in with the participant periodically during the stimulation to see whether they 
are comfortable. If any side -effect occurs (rated by the participant as stronger than 
“moderate”) or the participant is experiencing severe discomfort, the stimulation will be 
immediately stopped.  
 
There is a purely theoretical likelihood tha t stimulation of neuronal circuits can lead to 
epileptic discharges. To minimize this occurrence, we screen and exclude patients with 
personal and family history of neurological conditions from the study. If abnormalities or 
a seizure is witnessed during t he course of the study, a referral will be made to the UNC  
Department of Neurology  for follow -up. In the theoretical  event that a seizure is 
witnessed that involve s the loss of consciousness, the patient will be told not to operate a 
motor vehicle until cl eared by the DMV.  
 
Patients with MDD have an about 20 times higher rate of suicide than average. We have 
no evidence  that our treatment paradigms will in any way increase this likelihood. 
Patients with high suicide risk will not be included in this study.  If an enrolled patient 
shows signs of suicide risks that were not apparent during enrollment, a referral to UNC 
Psychiatry will be made. Dr. Rubinow, Co -I, will facilitate this process.  
 
We will be using the Suicidality Module included in the M.I.N.I 7.0 to assess suicide risk.  
Inclusion criteria states that the patient must be low suicide risk, potential participants  
that have an above “low risk ” designation  will not be eligible for the study. We will 
administer a daily questionnaire to assess suicide ris k. In the case suicide risk increases 
during participation in the study, the participant will be asked to stop the study and will 
be provided with a referral to UNC Department of Psychiatry and their mental health care 
or family medical doctor will be cont acted.  
 
2.3.2 Known Potential Benefits  
 
Major depressive disorder is a common, severe psychiatric illness. Patients with 
MDD exhibit elevated oscillatory activity in left dorso -lateral prefrontal cortex. Our 
novel approach introduces non -invasive brain stimulat ion for mental illnesses and has 
the potential to treat symptoms not only in depression but also schizophrenia, and 
anxiety disorders.  
 
This study has not been designed to benefit the individual participants. However, 
participants in this study may experi ence some degree of relief from mood symptoms 
as a resul t of tACS treatment. There are no serious risks to the participant from the 
treatment used in this study. The chance to understand and develop a new treatment 
18 
 for a wide range of psychiatric disorders  is an important step in helping the millions 
of people in the world who suffer from mental illness.  
19 
 3 OBJECTIVES  
3.1 Study Objectives  
 
Our primary objective is to conduct a pilot  clinical trial to establish  feasibility and to collect first 
effectiveness data for the use of tACS to renormalize pathological alpha oscillations in dl -PFC of 
unmedicated patients with MDD by comparing MADRS scores  from baseline and 5 week follow 
up visit.  
 
3.2 Study Outcome Measures  
 
3.2.1  Primary Outcome Measures  
 
The Montgome ry-Asberg Depression Rating Scale (Attachment 8) will be the primary 
outcome measures for this  study.  This measurement will be taken at baseline (first day of 
stimulation), l ast day of stimulation, at the 2  week and at the 4 week follow up visit s.   
We wi ll compare the MAD RS scores between baseline and 4  week follow up as our 
primary outcomes measure.  
 
3.2.2  Secondary Outcome Measures  
 
As a secondary outcomes measure , we will compare alpha oscillation power from resting 
state EEG recordings on the first an d last day of stimulation . We will also collect EEG 
data at the 4  week follow up visit. We will use th ese data to analyze alpha frequency 
activity as a pilot study  for de rivation  of EEG biomarkers.   
20 
 4 STUDY DESIGN  
The design for this study is a pilot, rand omized, double blind, sham -controlled, clinical trial 
which will be used to demonstrate feasibility and collect effectiveness data for further refinement 
of a tACS approach and for the subsequent design of a follow -up, multi -site, large -scale study.  
We are  recruiting from a clinical population.  For this clinical trial we are seeking 60 males and 
non-pregnant females ages 18 -65 with unipolar, non -psychotic MDD , free of benzodiazepine  and 
anticonvulsant medication, who have a Hamil ton Depression Rating Scale  > 8 and are at a low 
risk for suicide according to the Hamilton Depression Rating Scale .  All women of child -bearing 
potential will be asked to take a pregnancy test during the initial session in order to determine 
eligibility for the study. These individ uals will be outpatients and may seek mental health care 
from a family practitioner, therapist or psychiatrist.  
 
This is a single site, pilot clinical trial with 3 arms.  We estimate 2 years to complete study 
enrollment.   
 
Participants will be randomly as signed to one of three arms; active sham stimulation, 10 Hz 
(alpha) tACS or 40 Hz (gamma) tACS. Active sham treatment will include 10 seconds of ramp 
in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a to tal of 80  seconds of total 
stimulation.   The choice of an active sham is motivated to enhance success of patient blinding by 
mimicking skin sensations associated with tACS.  10 Hz and 40 Hz tACS will have a 10 second 
ramp in and ramp out with 40 minutes of stimulation for a total of 2420 second s. Stimulation 
waveform is a sine -wave with a peak -to-peak amplitude of 2 mA. In each arm, participants will 
stay in a relaxed and yet controlled state by watching a nature movie such as “Reefscape” during 
stimulation.  
 
Eligible participants who complete this clinical trial will have a total of 8 visits; an initial 
session, 5 days of stimulation, a 2  and a 4  week follow up visit.  The initial s ession will take 
approximately 3  hours, the first and last day of stimulation will take appr oximately 6  hours and 
days 2 through 4 of stimulation will take 1.5 hours each .  The one  week fol low up will take 
approximately 2  hours and the four  week fol low up will take approximately 4 .5 hours.  We 
estimate that total participant participation d uration will be approximatel y 26 hours.  
  
Our primary objective is to conduct a pilot clinical trial to establish the feasibility and to collect 
first effectiveness data for the use of tACS to renormalize pathological alpha oscillations in dl -
PFC of unmedicated patients with MDD com paring MADRS scores  from baseline to 4  week 
follow up visits. As a secondary objective we will assess the differential clinical effects of sham, 
10 Hz and 40 Hz tACS on EEG measures of alpha oscillations.  
 
21 
 5 Study Enrollment and Withdrawal  
 
5.1 Participant  Inclusion Criteria  
 
In order to be eligible to participate in this study, a participant must meet all of the following 
criteria:  
 
 Provide signed and dated informed consent form  
 Male or female, aged 18 -65 years  
 DSM -IV diagnosis of MDD; unipolar, non -psycho tic 
 Hamilton D epression Rating Scale score >8  
 Capacity to understand all relevant risks and potential benefits of the study (informed 
consent)  
 Meet criteria for low suicide risk  
 Willing to comply with all study procedures and be available to do so for the duration of the 
study  
 Women of reproductive potential must use highly effective contraception  
 At least 6 months since their last ECT session  
 
5.2 Participant Exclusion Criteria  
 
A potential participant who meets any of the following criteria will be exclu ded from 
participation in this study:  
 
 DSM -IV diagnosis of alcohol of substance abuse (other than nicotine) within the last month 
or a DSM -IV diagnosis of alcohol or substance dependence (other than nicotine) within the 
last 6 months  
 Medical or neurologica l illness (unstable cardiac disease, AIDS, malignancy, liver or renal 
impairment) or treatment for a medical disorder that could interfere with study participation  
 History of traumatic brain injury, reoccurring seizures or later cognitive rehabilitation , or 
causing cognitive sequelae  
 Prior brain surgery  
 Any brain devices/implants, including cochlear implants and aneurysm clips  
 Co-morbid neurological condition (i.e. seizure disorder, brain tumor)  
 Non English speakers  
 Pregnancy, nursing, or if female and fert ile, unwilling to use appropriate birth control 
measures during study participation  
 Anything that, in the opinion of the investigator, would place the participant at increased risk 
or preclude the participant’s full compliance with or completion of the stu dy  
22 
  Current  axis I mood,  anxiety,  or psychotic  disorder  other  than major  depressive  disorder.    
 Lifetime  comorbid  psychiatric  bipolar  or psychotic  disorder.                                             
 Eating  disorder  (current  or within  the past 6 months)                                                             
 Obsessive -compulsive  disorder  (lifetime)                                                                                
 PTSD  (current  or within  the last 6 months)                                                                             
 ADHD  (currently  under  treatment)          
 Current use of benzodiazepines and/or antiepileptic drugs                                                          
                         
 
5.3 Strategies for Recruitment and Retention  
 
This clinical trial will utilize multiple recruitment strategies in order to communicate this 
opportunity to as many potential participants as possible.  Our first means is  through a referral 
process.  Participants can be referred to the stu dy through their primary mental health care 
provider or family doctor during routine visits. This type of recruitment will take place in 
doctors’ offices throughout Chapel Hill, Carrboro, Durham and Raleigh areas. We estimate that 
approximately 20 particip ants will be enrolled from the Chapel Hill/Carrboro area and 1 0 
between Durham and Raleigh. Clinicians will be informed of inclusion criteria through email and 
listserv announcements and be asked to mention this clinical trial to appropriate patients  and 
offer them a flyer/ brochure  with contact information . Interested individuals can than call or 
email the secure line/address in order to set up a phone prescreening.  
 
We will also be posting ads in the local newspaper s including, the Independent Weekly.  In 
addition to newspapers we will have postings on websites such as  Clinica lTrials.gov and NAMI . 
We will have contact information  and a brief summary of the clinical trial posted  on the Frohlich 
Lab Facebook and Twitter page s.  These strategies  will assist i n recruiting medication free 
patients. Finally, with permission from Jennifer Rothman, the NIMH Outreach Partner for North 
Carolina, we will speak about our study and hand out fliers at NAMI Family to Family meetings. 
In addition to these recruitment strat egies, we will also be utilizing advertisements through 
Facebook and Craigslist, and have information about our study with study coordinator contact 
information on Join the Conquest, ClinicalTrials.gov, and Studypages.com. Interested 
individuals need simpl y to read the information about the study and contact the study coordinator 
to complete the phone screening.  
 
Our retention strategy includes a payment schedule of four times per participant. The participant 
will receive payment at the initial session, the  5th day of stimulation, and both follow up session s, 
at the final follow up session will include  a completion bonus of $20.00. The research staff will 
also give each participant a reminder call for the initial session, the first day of stimulation, and 
each follow up session. Each research staff member will be easily available for the participants to 
contact  via email or phone. The inclusion criteria state that each participant must be able to 
23 
 understand all risks and benefits associated with this study. W e will be asking each participant to 
answer questions about the consent form to determine that the study process and the duration of 
participation are completely understood by all participants. We will aim to have a specific 
research team member assigned t o complete all sessions with the same participant . However we 
will not require the same researcher to be present during stimulation sessions 2 through 4 .  The 
study team will work hard at forming a professional relationship with the participant so they fee l 
comfortable and willing to discuss what may be sensitive information. Retention will be 
quantified  by the fraction of participant s coming to each scheduled session (the data from each 
session will be scored and documented the day of the session). Partici pants  will no longer be 
eligible to continue the study if they miss any stimulation session.  
5.4 Treatment Assignment Procedures  
 
Participants will be randomized into one of three arms .  This is a double blind study, so neither 
the participant nor the rese archer will know which treatment the partici pant is receiving, if any .   
 
5.4.1  Randomization Procedures  
 
Kristin Sellers will randomize 60 codes which will be used by the study coordinator and 
research assistants.  These codes are directly linked to which  treatment participants 
receive (sham, 10Hz tACS or 40 Hz tACS).  Kristin Seller s has no other responsibility in 
the study other than providing these randomized codes.   
 
5.4.2  Reasons for Withdrawal  
 
A study participant will be discontinued from further p articipation if : 
 
 A participant answers yes to any of the daily suicide questionnaires.  
 A participant has a YMRS score greater than or equal to 12.  
 The participant has missed any day of stimulation.  
 Any clinical adverse event (AE), laboratory ab normality,  intercurrent illness  or other 
medical condition , or situation occurs such that continued participation in the study 
would not be in the best interest of the participant.  
 The participant meets any exclusion criteria (either newly developed or not previousl y 
recognized).  
 A participant wishes to withdraw from further participation for any reason . 
 
24 
 5.4.3  Handling of Withdrawals  
 
We will collect safety data on any participant discontinued because of an AE or SAE.  In 
any case, every effort will be made to under take protocol -specified safety follow -up 
procedures.  If voluntary withdrawal occurs, the participant will be asked to  continue 
scheduled evaluations and  complete an end -of-study evaluation .  If an AE has been 
reported, researchers will help the participan t seek the medical care they need and a 
follow up will be performed by the PI and Co -I.  In the case of an early withdrawal, the 
researcher will complete a Participant Off Study form to document the withdrawal reason  
(Appendix S ). 
 
5.4.4  Termination of Stu dy  
 
This study may be prematurely terminated if, in the opinion of the investigator, there is 
sufficient reasonable cause.  Circumstances that may warrant termination include, but are 
not limited to:  
 
 Determination of unexpected, significant, or unaccepta ble risk to participants.  
 Insufficient adherence to protocol requirements.  
 Data those are  not sufficiently complete and/or evaluable.  
 Plans to modify suspend or discontinue the development of the study device.  
 
The IRB will be informed promptly and provid ed the reason(s) for the termination or 
suspension by the sponsor or by the investigator/institution, as specified by the applicable 
regulatory requirement(s).  
25 
 6 STUDY INVESTIGATIO NAL PRODUCT  
6.1 Study Product Description  
  
We will be using a transcranial current stimulator designed in the Frohlich Lab for 
investigational research purposes  and the Neuroconn devices used in pervious IRB approved 
studies .  The device is not implanted and has not been designed for or being used to support or 
sustain human life . This device does not have a potential for serious risk to the health, safety, or 
welfare of the participant. There has never been an instance of serious side -effect reported due to 
use of transcranial brain stimulation. Previous studies in the Frohlich L ab that used comparable 
devices have always been classified as “non -significant risk” by the UNC IRB.  
 
In addition, some participants will be stimulated with the commercial, CE -certified Neuroconn 
Plus stimulator (for purely logistic reasons of device avai lability). The use of this device in this 
study has previously received a NSR designation on initial review by the full UNC IRB. Both 
devices are electrically equivalent and provide the same stimulation. The NeuroConn device 
description is as follows:  
 
The DC-STIMULATOR is a CE -certified medical device for conducting non -invasive 
transcranial direct -current stimulation (tDCS) in humans. DC stimulation is used in clinical 
practice and in the research of stroke, epilepsy, migraine, tinnitus, depression, multi ple sclerosis, 
dementia and chronic headache. The DC -STIMULATOR is a micro -processor -controlled 
constant current source. It meets the highest safety standards thanks to (hardware - and software -
based) multistage monitoring of the current path. By continuous ly monitoring electrode 
impedance it can detect insufficient contact with the skin and automatically terminate 
stimulation, maximising patient safety.  
The device's alphanumeric display and the 4 touch keys allow various stimulation modes to be 
selected and  stimulation parameters such as current strength, duration, fade -in and fade -out to be 
set. 
 
DC-STIMULATOR features:  
• 1 channel (anodal and cathodal stimulation possible)  
• Adjustable current up to 5,000 µA *  
• Adjustable application time up to 30 minutes  * 
• 2 standard modes - single (continuous stimulation) and - pulse (cyclical stimulation 
activation/deactivation) with fade in and fade out  
• Customer -specific programs possible (optional)  
• "Study mode" for blind processing of genuine and 'pseudo' stimul ation (optional)  
• External trigger input (optional)  
 
 
6.1.1  Device Description  
 
The device consists of the following main components/subsystems:  
26 
  
1. Tablet with user interface application (App)  
2. Microprocessor  
3. Function generator chip  
4. Voltage contr olled current source  
5. Safety circuitry  
 
First, the stimulation parameters are specified by the user through the app.  The 
parameters are:  
 
1. tDCS/tACS  
2. Number of channels  
3. Amplitude  
4. Test duration  
5. Frequency (for tACS)  
6. Password.  
 
Next, the pa rameters are sent via Bluetooth to the microprocessor.  The microprocessor 
interprets these parameters, and programs the function generator chip accordingly.  The 
function generator then creates the programmed waveform, which is ultimately a voltage 
signal .  The voltage signal is applied to a voltage controlled current source, which 
generates the specified amount of current through an arbitrary load resistance.  
 
 
 
6.1.2  Operation  
 
A. The desired current value is scaled to a register value and stored in the function 
generator.  
 
B. The value in the register determines the percent of full scale output current, generated 
by the function generator.  
 
C. The generated current waveform from the function generator is driven through a 
specified resistance.  The result ing voltage drop is amplified by an instrumentation 
amplifier.  
 
D. The voltage waveform from the output of the instrumentation amplifier is applied to a 
voltage controlled current source.  
 
27 
 Current Sensor Circuit  
A 33.2 Ω sense resistor is placed in series  with the stimulation electrodes on the high 
side.  Since high -side current sensing is used, any short circuit of the electrode terminals 
to ground will be detected.  The stimulation current flows through this resistor and 
generates a voltage.  The voltage  across this resistor is sensed and amplified by the 
AD628 difference amplifier.  The gain of the difference amplifier is set to 9.9039.  The 
current sensor voltage is then shifted before it is read by the microprocessor and the 
hardware overcurrent safety  feature.   
 
Voltage Sensor Circuit  
The differential voltage across the electrodes is measured so that the impedance can be 
calculated.  The voltage is measured by buffering the positive electrode and negative 
electrode each with a unity gain op -amp circui t.  The voltage sensor output is then shifted 
before it is read by the microprocessor using the same level shifting circuit described in 
the current sensor section.   
 
6.1.3 Safety Precautions  
 
The device is equipped with 4 different stages of safety prote ction, all of which protect 
the stimulant from high currents.  The stages are as follows:  
 
1. Automatic software current cutoff.  The output of the current sensor described above is 
read by a microprocessor, which compares the reading to a value of +/ -3mA peak.  If the 
current exceeds these limits, stimulation is stopped, a relay in series with the electrode is 
opened, and the power supply used for stimulation is turned off.  The user is then given 
the option to investigate the issue, and cancel or resume t he test.  Since high -side current 
sensing is used (described above), any short circuit of the electrode terminals to ground 
will be detected.  
 
2. Automatic hardware current cutoff.  The output of the current sensor is fed into a pair 
of comparators which d etect if the current exceeds +/ -4.5mA.  If so, the fault is latched 
such that the relay in series with the electrodes is opened.  Additionally, the 
microprocessor is notified of this instance through an interrupt.  Upon this interrupt, the 
microprocessor i mmediately stops stimulation and the power supply used for stimulation 
is turned off.  
  
Figure 1: Example of successful hardware cutoff function  
 
28 
 
 
 
 
3. Permanent hardware current cutoff.  A 5mA fast -acting fuse is in series with the 
electrode connector.  If the above two over -current detection methods fail, the fuse will 
blow, and the stimulant will no longer be electrically connected to the device.  
 
4. Power supply fuse.  Finally, if for any other reason the entire device draws too much 
current, the main  power supply fuse is blown.  This fuse is sized with a cutoff of 200% of 
steady -state operating current.  
 
6.2 Preparation and Administration of Study Investigational Product  
 
After participants have completed the daily questionnaires, they will be comfort ably seated.  The 
research team will first measure their heads electrode placement using the 10 -20 system.  
Participants will then be fitted with the 3 electrodes for stimulation. The participant will be in the 
relaxed yet, experimentally controlled state by watching a nature movie. One session of 
stimulation will be performed per day, for 40 minutes.  In the 10 Hz and 40 Hz groups 
stimulation will have a 10 second ramp in and ramp out with 40 minutes of stimulation for a total 
of 2420 seconds. Stimulation waveforms are sine -waves with a peak -to-peak amplitude of 2 mA. 
 The sham stimulation will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a Yellow: Relay control line  
Green : Current through 
electrode (goes from 
negative current to zero)  
Blue: Current sensor 
output (has lowpass filter)  
Purple : SR latch output  
 
29 
 ramp out of 10 seconds for a total of 100 seconds of stimulation  Electrodes will be saline soaked, 
5x5cm and placed over F3 and F4 with a 5x7cm placed over CZ as a return electrode.   
 
Stimulation devices will be preprogrammed and codes will be randomized to one of the three 
experimental arms. Researchers will enter the participant -specific code into the Ap p that controls 
the simtulation  and monitor participants during the 40 minutes of the stimulation.  
 
The study coordinator and/or the research assistant will be thoroughly trained and have trainings 
documented on the transcranial stimulation device and will  be present during all stimulation 
sessions. Please see Appendix R for an example of the training documentation log. To monitor 
side effects of stimulation a daily questionnaire will be administered after each stimulation 
session.  Please see Attachment 6 for an example of the daily stimulation questionnaire, and 
Attachment 7 for an example of the endpoint stimulation questionnaire.  
 
6.3 Assessment of Participant Compliance with Study Investigational 
Product  
 
Compliance for this study includes making all 5  stimulation sessions. Follow up periods will be 
able to take place ±3 days of scheduled visits.  
30 
 7 STUDY SCHEDULE  
Dr. Cordle or other approved clinician will be present during the 1st day of stimulation, the 5th 
day of stimulation, the 2  week and the 4  week follow up s to administer the CGI (Attachment 3) 
until research personnel are comfortable and certified to do so (will be determined by 
accompanying clinician). In order to increase data quality , the assessments for an individual 
participant at the initi al session, the 1st day of stimulation, the 5th day of stimulation, the 2 week 4  
week follow up s will be administered by the same researcher. Protocol for this study will not 
require the same researcher to be present during days 2 through 4 of stimulation although  the 
team will strive to schedule the same researcher for every session.  
 
7.1 Screening  
 
Screening Telephone Call  
 
Individual s who are referred by a mental health care provider will be contacted by a research for 
an initial phone screening .  Resea rchers will keep a Telephone Contact log for each telephone 
conversation with a participant throughout the study. There will be a log for each participant and 
will be filed in the participant binder  (Appendix I ).  
 
During the telephone screening , researche rs will provide a brief background about MDD and 
tACS.  Any initial question s will be answered at this point. The timeline of visits will then be 
explained; there will be 1 to 8 sessions, with 1 initial session, 5 consecutive week days of 
stimulation , 2 follow up  sessions  2 week s after the final stimulation and another 4 weeks after 
final stimulation. The participant will be informed that compensation for their participation will 
be received at 3 sessions  throughout the study; the initial session,  last day of stimulation, and at 
the 4  week follow up. The participant will be asked if they have any additional questions.  Once 
all questions have been answered, the participant will be asked if he/she is still interesting in 
participating in the study.  If yes, t he researcher will begin the initial phon e screening which will  
determine eligibility for the initial session. The screening questions are shown below. If the 
required answers are given for each question, the initia l session will be scheduled and  a reminde r 
call will be given  at least 24 hours before initial session . We will use the telephone script 
provided in Appendix T  for all telephone screenings .  
 
 Are you 18 years old or older?  (Yes)  
 Have you ever, or are you currently being treated for a neurologica l condition (i.e. 
epilepsy, migraines, etc)? (No)  
 Are you currently taking medication for the treatment of depression or any other 
psychiatric  illness? (No)  
o Have you ever taken medication for a mood disorder?  
o If yes, has it been at least 6 months since th en? 
31 
  How long have you been depressed?  
 What steps have you taken to treat this depression?  
 Have you ever had brain surgery? (No)  
 Do you have any brain devices or implants, including a cochlear implant or aneurysm 
clip? (No)  
 Have you ever been diagnosed wit h a traumatic brain injury? (No)  
 For females only, is there a chance you may be pregnant? (No)  
Follow -up Questions  
 Have you been diagnosed with Major Depressive Disorder by a professional (i.e. a 
psychiatrist or other licensed clinician)?  
 Have you ever bee n hospitalized?  
o If yes, was it in anyway related to a mood disorder or psychiatric condition?  
o If yes, when did this occur?  
 
7.2 Enrollment/Baseline  
 
Initial Session Visit (Visit 1, Day 0)  
 
At the initial session participants will sign both a HIPAA authori zation form and the cons ent 
form. Each form will be read to the participant  by the researcher, and the participant will be 
given the time to ask any questions about the information discussed. Each participant will be 
asked a series of questions (Appendix E ) to ensure that the consent form is fully understood.  
 
Once consent is obtained, the researcher will verify that the participant meets inclusion criteria. 
If the participant is female, and unsure of pregnancy status, she will be asked to complete a urine  
pregnancy test to verify status. Next, demographic information will be collected, which will 
include a history of medication, alcohol, and drug use. This information is used to verify that the 
participant does not have an existing alcohol or drug dependen cy or disorder.  A short handedness 
questionnaire will also be administered. Once the questionnaires and tasks are complete, t he 
researchers will perform an 8  minute  EEG recording. Participants will be asked to keep eyes 
open for 4  minutes  and then keep eye s closed for 4  minutes during the recording. After the 
resting state EEG recording, the participant will be administered the “n -back” working memory 
task for a total of 20 minutes while a second EEG is being recorded. The n -back will be 
administered during  each EEG recording following the resting state EEG. The following 
questionnaires will then be administere d to further check eligibility; The Mini International 
Neuropsychiatric Interview (MINI) to confirm diagnosis  and suicide risk,  and the Hamilton 
Depre ssion Rating Scale 17 item (HDRS17) will be used to assess the severity of depression 
(Attachment 5).  At the end of the initial session, and once eligibility has been confirmed, a 
saliva sample will be collected  (for testing of BDNF allele) , the week of s timulation will be 
scheduled, and the participant will be paid.  
 
32 
 7.3 Stimulation Sessions  
 
Day 1 of Stimulation (Visit 2)  
 
At the first day of stimulation, several questionnaires will be administered. First, the suicide 
assessment ( Attachment 4 ), and YMRS  (Attachment 10 ) will be administered to assess safety. 
These assessments will be administered at the beginning of each study visit. If the participant 
shows any development of SI, SB or manic symptoms, their participation will be stopped and 
their primary  mental health care provider or family physician will be contacted.  In the case that 
they do not see anyone for their depression, Dr. Cordle  will assist the participant in seeking 
medical care .  
 
Next, the HDRS17 ( Attachment 5 ), MADRS ( Attachment 8 ), BDI (Attachment 1 ), and CGI 
(Attachment 3 ) will be administered. These tools are used to collect information on the 
participant’s symptom severity and are administered multiple times throughout the study. 
Baseline cognitive function tests will follow the sympt om scale and include; the MOCA 
(Attachment 9 ) and the n -back  working memory task .  
 
Once the questionnaires and tasks are complete, t he researchers will perform a n 8 minute  EEG 
recording. Participants will be asked to keep eyes open for 4  minutes  and then keep eyes closed 
for 4  minutes during the recording. After the resting state EEG recording, the participant will be 
administered the “n -back”  working memory  task for a total of 20 minutes  while a second EEG is 
being recorded . The n -back will be administere d during each EEG recording following the 
resting state EEG.  Then the participant will undergo either  a sham, 10 Hz or 40Hz tACS 
treatment for 40 minutes. Participants will stay in a relaxed yet experimentally controlled state 
by watching a nature movie su ch as “Reefscape” during stimulation.  
 
Finally, to assess any side effects of stimulation, the stimulation adverse effects questionnaire 
will be administered. This questionnaire will be administered at the end of each stimulation 
session ( Attachment 6 ).  
 
Days 2 – 4 of Stimulation (Visit 3 – 5) 
 
The Suicide Assessment ( Attachment 4 ) and the YMRS ( Attachment 10 ) will continue to be 
administered at the beginning of each session. Once safety is assessed, and it is determined to be 
safe to continue, the partic ipant will receive 40 minutes of sham, 10 Hz or 40Hz tACS (as per the 
initial randomization) while watching the assigned movie.  The stimulation session will be 
followed by the stimulation adverse effects questionnaire ending the session.  If the participa nt 
shows any development of SI, SB or manic symptoms, their participation will be stopped and 
their primary mental health care provider or family physician will be contacted.  In the case that 
33 
 they do not see anyone for their depression, Dr. Cordle  will as sist the participant in seeking 
medical care .  
 
Day 5 of Stimulation (Visit 6)  
 
The Suicide Assessment ( Attachment 4 ) and the YMRS ( Attachment 10 ) will be administered at 
the beginning of the session. Once safety is assessed and it is determined to be safe to continue, 
the participants will receive 40 minutes of either sham, 10 Hz or 40Hz tACS (as per the initial 
randomization) while watching the assigned movie, followed the stimulation adverse effects 
questionnaire. The HDRS17 ( Attachment 5 ), MADRS ( Attach ment 8 ), BDI ( Attachment 1 ), and 
CGI ( Attachment 3 ) data collection assessments will be administered during this session. After 
the assessments are completed, an 8  minute EEG will be administ ered, with 4 minutes of eyes 
open and 4  minutes of eyes closed.  Following this, the participant will perform the “n -back” 
working memory test for a total of 20 minutes.  The participant will be paid at the end of this 
session for the completion of 5 stimulation sessions.  
 
 
7.4 Follow -up  
 
2 Week Follow -up Vis it (Visit 7 , 2 weeks after final  day of stimulation)  
 
The Suicide Assessment (Attachment 4) and the YMRS (Attachment 10) will be administered at 
the beginning of this session. The HDRS17 (Attachment 5) , MADRS (Attachment 8) , BDI 
(Attachment 1) , and CGI (Attachment 3)  assessments will be administered after safety has been 
assessed.  
 
7.5 Final Study Visit  
 
4 Week Follow -up Visit (Visit 8, 3  weeks after first follow up visit)  
 
The Suicide Assessment (Attachment 4) and the YMRS (Attachment 10)  will be administered at 
the beginning of this session.  The participant will be asked to recall their experience of 
stimulation and answer the final stimulation adverse effects questionnaire  (Attachment 7) .  This 
questionnaire will ask the participant whether they believed they recei ved treatment (answer 
options include yes, no, and I don’t know) and whether they thi nk their symptoms have 
improved.  The HDRS17 (Attachment 5) , MADRS (Attachment 8) , BDI (Attachment 1) , and 
CGI (Attachment 3) assessments will be administered, followed by  the MOCA (Attachment 9) 
and n-back working memory task. After the cogniti ve assessments, a final 10 minute EEG will 
be administered, with 5 minutes of eyes open and 5 minutes of eyes closed. The participant will 
be paid at the end of this session includin g the study completion bonus.  
34 
 8 STUDY PROCEDURES/E VALUATIONS  
8.1 Clinical Evaluations  
 
During the initial session, researchers will collect demographics. Participant demographics 
include medical history and medication history.  This information is used to confirm inclusion 
criteria; CNS medications free for at least 6 months, and no current alcohol and drug abuses or 
disorder exist.  
 
Several clinical evaluations will be used throughout this study. These assessments are listed 
below and can be found in the a ttached documents.  
 
i. The Mini International Neuropsychiatric Interview (MINI) is a short, structured interview 
that will be used during the initial session to confirm diagnosis of MDD, unipolar and non -
psychotic  with a low suicide risk . This scale has been validated as being a reliable diagnostic 
tool (Sheehan et al. 1998).  
 
ii. The Hamilton Depression Rating Scale 17 -item (HDRS17) (William s 2001; Khan et al 2002; 
Leentjens et al. 2000) will be administered during the initial session, day 1 of stimulation 
(basel ine), day 5 of stimulation and at the 3 and 5 week follow ups. This scale is used to 
determine patient eligibility and to monitor the severity of the participant’s depression  
symptoms . (Attachment 5)  
 
iii. The Beck Depression Inventory (BDI) (Beck et al. 1988; Dozois et al. 1998) will be 
administered at baseline, day 5 of stimulation and at week 3 and 5 follow up. The BDI is a 
21-item, self -report rating inventory that measures characteristic attitudes  and symptoms of 
depression  and will be used  to monitor the s everity of the patient’s depression throughout the 
study. (Attachment 1)  
 
iv. The Clinical Global Impression scale (CGI) (Khan et al. 2001) will be administered at 
baseline, day 5 of stimulation and at week 3 and 5 follow up. The CGI will be used to 
monitor th e severity of the patient’s symptoms and also as a measure of treatment response 
and efficacy. Dr. Cordle or other approved clinician will be present during the 1st day of 
stimulation, the 5th day of stimulation, the 2 week  follow up and the 4  week follow up to 
administer the CGI until research personnel are comfortable and certified to do so. 
(Attachment 3)  
 
v. The Montgomery -Asberg Depression Rating Scale (MADRS) (Khan et al. 2001; Leentjens et 
al. 2001) will be administered at baseline, day 5 of stimulation  and at week 3 and 5 follow 
up. This scale will be used as a primary outcome of this study and will be used to measure 
35 
 the severity of depressive episodes experienced by participants. (Attachment 8)  
 
We will be monitoring the safety of our participants thr oughout the study with the following 
assessments. These assessments can also be found in attachments.  
 
i. A suicide questionnaire previously used in IRB # 14 -0600 will be used at each session of 
this study. This questionnaire tracks suicidal ideation and beha vior.  Participants will be 
asked to answer whether they have had any thoughts of hurting themselves within the 
past 24 hours and whether they have hurt themselves within the past 24 hours. If a 
participant admits to experiencing either SI or SB their part icipation will be stopped 
immediately and their primary mental health care provider or family physician will be 
contacted.  In the case that they do not see anyone for their depression, Dr. Cordle  will 
assist the participant in seeking medical care . (Attac hment 4)  
 
ii. A stimulation adverse effects questionnaire will be administered at the end of each 
stimulation session and at the 5 week follow visit. This questionnaire will be used as a 
safety measure and to collect data on participant experience. A similar q uestionnaire was 
used in IRB 13 -2995 to determine ability to successfully blind using transcranial current 
stimulation.  (Attachment 6 and Attachment 7)  
 
iii. The Young Mania Rating Scale (YMRS) (Young et al. 1978) was designed to assess the 
severity of manic s ymptoms at baseline, with the ability to reassess the individual’s 
symptoms over time. When undergoing treatment for depression, a possible effect of 
treatment is to alter the serotonin levels, potentially causing a manic episode. Although 
we do not expect  such an event to occur since we are not using a  medication that targets 
serotonin levels, we will be conduct ing this assessment at each evaluation as a 
precautionary measure. In the case a participant develops any sign  of mania their 
participation in the study will be stopped and their primary mental health care provider or 
family physician will be contacted.  In the case that they do not see anyone for their 
depression, Dr. Cordle  will assist the participant in seeking medical care . (Attachment 10)  
8.2 Laboratory Evaluations  
 
8.2.1  Clinical Laboratory Evaluations  
 
During the initial session, a urine pregnancy test will be performed for any female 
participant who is unable to confirm pregnancy status. This information will be recorded 
on the inclusion/exclu sion criteria checklist (Appendix H) to be completed by the 
researcher.  
 
36 
 8.2.2  Special Assays or Procedures  
 
Two cognitive assays will be administered in order to assess cognitive abilities at 
baseline and again at the study endpoint. The Montreal Cognitiv e Assessment (MOCA) 
(Attachment 9 ) will be used to monitor changes in cognition since it has been developed 
to detect changes in cognition. In addition, an n-back working memory task will be 
administered  during each EEG recording .  This task is designed to  detect changes in 
working memory performance that has been associated with overall functional integrity 
of neuronal circuits in the prefrontal cortex.  
 
There will be two procedures used throughout this study. Each participant will attend 5 
consecutive wee kdays of stimulation for this study. Each participant will be randomly 
assigned to one of three treatment arms for this study (sham, 10HZ active tACS or 40 Hz 
active tACS). Electrodes with measurement 5x5cm will be placed over F3 and F4, and a 
return elect rode, 5x7cm , will be placed over Cz. In order to detect a ny change(s) at  the 
neurophysiological level , an EEG will be performed during the 1st day of stimulation, the 
5th day of stimulation, and at the 5 week follow up session. This measurement will 
contri bute to the design of novel network -level biomarkers of MDD and of treatment 
response.   
In addition to the above procedures, we will be collecting a saliva sample at the initial 
visit.  This sample will be used to test for a single nucleotide polymorphism  in the  BDNF  
gene whose  presence may have an influence  on effectiveness of brain stimulation.  
Within the central nervous system, BDNF regulates survival, proliferation, and synaptic 
growth as well as directly influences synaptic plasticity in the adult h uman brain (Antal et 
al. 2010).   Egan et al. (2003) demonstrate d that Val66Met, a single nucleotide 
polymorphism in the BDNF  gene , has functional consequences in healthy humans 
including decreased episodic memory and hippocampal inducing a reduction in  recall 
capacity.  This polymorphism is common in over one third of the Caucasian population 
(65% Val66Val to 35% Val66MET) (Pezawas et al. 2004; Hariri and Weinberger 2003).   
Kleim et al. (2006)  found that individuals with the Val/Val polymorphism respond to 
tDCS and transcranial magnetic stimulation treatments (TMS) with expected changes 
whereas individuals expressing the Val/MET allele do not.   These authors indicate the 
difference to be caused by the impairment in synaptic plasticity caused by the  Val/MET 
allele. These findings suggest that individual efficacy of treatments using brain 
stimulation may be partially genetically predetermined and should be taken into account 
when preforming such procedures. Accordingly, we will conduct genotyping of all 
particip ants in this study in order to assess BDNF status.  We will perform exploratory 
analyses in which we group participants by BDNF status.  
  
37 
 9 ASSESSMENT OF SAFE TY 
9.1 Specification of Safety Parameters  
 
There will be three different assessments used to ensur e participant safety. First, the Suicide 
Assessment (Attachment 4) will be administered at the beginning of each session.  This 
assessment is used to determine SI and SB within the past 24 hours. If the participant answers 
“Yes”  to either question, partici pation in the study will be stopped and their primary mental 
health care provider or family physician will be contacted.  In the case that they do not see 
anyone for their depression, Dr. Cordle  will assist the participant in seeking medical care .  
 
Immedi ately following the Suicide Assessment, the YMRS (Attachment 10) will be 
administered.  This assessment is used to detect any emergence of manic symptoms. If any 
manic symptoms become apparent, participation in the study will be stopped and their primary 
mental health care provider or family physician will be contacted.  In the case that they do not 
see anyone for their depression, Dr. Cordle  will assist the participant in seeking medical care .  
 
After each stimulation session, a stimulation adverse effects  questionnaire  (Attachment 6)  will be 
administered.  This tool is used to document any side effects experienced during stimulation. The 
researcher will also check with the participant throughout the 40 minute stimulation sessions to 
make certain no discomf ort is felt.  The stimulation session will be terminated if the participant 
reports having unmanageable discomfort or pain  (more than “moderate”) .  Additionally, this 
information will be reported on an AE report form (Appendix L) and an AE log (Appendix J) . 
 
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  
 
9.2.1  Adverse Events  
 
Adverse Event:   An AE, as defined by the NIH, is any unfavorable changes in health, 
including /abnormal laboratory findings that occur in trial parti cipants during the clinical 
trial or within a specified period following the trial.  
 
All AEs including local and systemic reactions not meeting the criteria for “serious 
adverse events” will be c aptured on the appropriate CRF.  I n addition , the AE Report 
Form will be completed by the study coordinator  (Appendix L ).  The AE report form 
includes the follow; what is known about the therapy and previous reported side effects, 
if the AE occurred in temporal relation to the therapy, whether or not the AE improve s or 
disappears when  treatment is stopped, whether the AE is a worsening of baseline 
symptoms or related to a concurrent medical condition or medication use. Once complete , 
38 
 this form will be given to the PI and the Co -I who will review , comment and sign th is 
form.  Completed forms will be placed in the participant’s folder.  
 
The study coordinator will document any AE occurrence on the AE log  (Appendix J ) 
which includes information such as the date of the AE, severity, relationship to the 
treatment (assesse d by the PI), actions taken, and outcome (s). The log will be reviewed 
and initialed by the PI 72 hours after being completed. All AEs occurring during the 
clinical trial will be documented appropriately regardless of relationship to tACS. All 
AEs will be f ollowed to adequate resolution and will be graded for severity and 
relationship to the study treatment.  Any medical condition noted at the initial session 
will be considered as baseline and not reported as an AE.  
 
  All AEs will be graded for severity usi ng the following guidelines.  
 
 Asymptomatic:  the participant is exhibiting no symptoms due to the event; no 
treatment needed.  
 Mild  Adverse Event – Event results in mild or transient discomfort, not requiring 
intervention or treatment; does not limit or inte rfere with daily activities (e.g., 
insomnia, mild headache).  
 Moderate  Adverse Event – Event is sufficiently discomforting so as to limit or 
interfere with daily activities; may require interventional treatment (e.g., fever 
requiring antipyretic medication) .  In the case of a moderate adverse event the medical 
advisor may recommend an over the counter medication.  
 Severe and undesirable  Adverse Event – Event results in significant symptoms that 
prevents normal daily activities; may require hospitalization or invasive intervention 
(e.g., anemia resulting in blood transfusion).  
 
Changes in the severity of an AE will be documented with the Note to File document  
(Appendix G ) and will be filed in the participant’s folder.  
 
Relationship to Study Products:   The PI and Co -I will together determine  whether an 
AE is associated with the study treatment. The event will be labeled associated if the 
event is temporally related to the administration of the therapy and no other factors can 
explain the event. The event will be  labeled as not associated if the event is temporally 
independent of the study treatment and can be explained by external factors such as major 
life events.  
 
39 
 9.2.2  Expected Adverse Reactions  
 
Transcranial current stimulation has been used without reports o f any serious side -effects. 
Some subjects report a transient mild tingling, burning, or itching  underneath the 
electrodes and headache, but no other side effects have been noted. Importantly, it 
remains unclear if these mild side effects were caused by the  transcranial brain 
stimulation. During the stimulation, the researcher will ask the participant about their 
comfort.  Stimulation will immediately be stopped if any discomfort (more than 
“moderate”) is reported. In theory, there is a possibility that appl ication of weak 
stimulation current could induce a seizure.  
 
These adverse reactions will be monitored with the stimulation adverse effects 
questionnaire  (Attachment 6) . The following scale reflects the scoring of severity for any 
possible side effects.  
 
1 = Absence of the indicated symptom  
2 = Mild (awareness of a symptom but the symptom is easily tolerated)  
3 = Moderate (discomfort enough to cause the researcher to be informed)  
4 = Severe (incapacitating; the stimulation is terminated due to extreme dis comfort)  
 
All expected adverse reactions questionnaires are a daily source document that will be 
placed in each individual’s folder.  Additionally, this data is imported directly into the 
RECap secure data base. Should the DSMB ask to see a complete report  of this 
information we can generate a report using REDCap.   
 
9.2.3  Serious Adverse Events  
 
Serious Adverse Event (SAE):  An SAE, as defined by the NIH, consists of adverse 
events that result in death, require either inpatient hospitalization or the prolon gation of 
hospitalization, are life -threatening, result in a persistent or significant 
disability/incapacity or result in congenital anomaly/birth defect. Other important medical 
events, based upon appropriate medical judgment, may also be considered Serio us 
Adverse Events if a trial participant’s health is at risk and intervention is required to 
prevent an outcome mentioned.  
 
All SAEs will be recorded on the Serious Adverse Events Form  (Appendix M ), 
documented in the UE/SAE log and reported to the IRB. Th e SAE Form will be 
completed by the study coordinator, and includes information relating to the onset and 
nature of the SAE, relationship to the study treatment, seriousness of the SAE, treatment 
required as a response to the SAE, and outcome. This form wi ll be filed in the 
40 
 participant’s binder at the resolution of the event. The study coordinator will complete the 
UE/SAE log (Appendix K ) which includes information such as the date of the event, time 
at which the study team was informed of the event, detai ls, when the IRB has been 
notified, and the date that the SAE Form was completed.  
 
9.2.4  Unanticipated Problems . 
 
Unexpected Events (UE) will be recorded on the UE/SAE log  (Appendix K  ) and will 
include information such as the date of the event, when the study team was informed of 
this event, details of the event, when the IRB was notified, and whether the SAE Form 
was completed. The IRB will be notified of each UE that may occur during the study.  
 
The Office for Human Research Protections considers unant icipated problems involving 
risks to participants or others to include, in general, any incident, experience, or outcome 
that meets all of the following criteria:  
 
 Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures 
that are described in the protocol -related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the participant 
population being studied;  
 Related or possibly related to participation in the resea rch  
 Suggests that the research places participants or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously 
known or recognized.  
 
If an UE occurs the IRB will be notified and the study will be a djusted as needed to 
protect the health and safety of the participants. Depending on the nature of the UE, the 
research protocol, inclusion/exclusion criteria, and informed consent will be changed to 
reflect the possibility of this event reoccurring. Pleas e see Appendix D for an example of 
the Consent Amendment Tracking log.  During this time, no new participants will be 
recruited and the research procedures for currently enrolled participants will be stopped. 
Each UE will be recorded and reported throughout  the study.  
 
9.3 Reporting Procedures  
 
We will be adopting the follow table for reporting procedures:  
 
What Event is Reported  When is Event Reported  By Whom is Event 
Reported  To Whom is Event 
Reported  
41 
 Fatal or life -threatening 
unexpected, suspected 
serious adverse reactions  Within  24 hours  of initial 
receipt of information  Investigator   Local/internal IRBs  
      
Non-fatal, non -life-
threatening unexpected, 
suspected serious adverse 
reactions  Within  48 hours of initial 
receipt of information  Study Coordina tor   Local/internal 
IRBs/Institutional 
Officials, DSMB  
Unanticipated adverse 
device effects  Within  10 working days of 
investigator first learning 
of effect  Investigator   Local/internal IRBs  
 
Unanticipated Problem 
that is not an SAE  Within  7 days  of the 
investigator becoming 
aware of the problem  Investigator   Local/internal 
IRBs/Institutional 
Officials,  
 
All Unanticipated 
Problems  Within  30 days  of the 
IRB’s receipt of the report 
of the UP from the 
investigator.  IRB  OHRP  
Investigator3  External IRBs  
 
9.3.1 Reporting of Pregnancy  
 
Pregnancy test s will be administered at the initial session  to all women of child -bearing 
potential .  There are no studies that suggest tACS would interfere with pregnancy.  
However, should a participant become pregnant during th e study their participation will 
be immediately terminated and will be sent to consult with Co-I and medical  monitor .   
 
9.4 Type and Duration of Follow -up of Participants after Adverse Events  
 
Medical monitors and Co-I will follow up with participants wit h in one week of an AE.  
 
9.5 Halting Rules  
 
If a seizure occurs  at the time of a study visit , a temporary hold will be placed over the study and 
further investigation will ensue. This could lead to stopping the study prematurely or continuing 
on with furth er safety measures in place. If two seizures are witnessed  during the study visits , the 
entire study will be stopped prematurely. These individuals would be referred for further medical 
attention. It is very unlikely that a seizure will occur, given that p revious studies using tDCS in 
patients with depression and schizophrenia have had no seizures occur (Berlin et al., 2013, 
Brunelin et al., 2012). The study w ill also be stopped (at least temporarily) if studies provide  
evidence that transcranial current st imulation caused brain damage or other harmful effects on 
42 
 subjects, either short -term or long -term.  
 
9.6 Safety Oversight  
 
Safety oversight will be under the direction of a DSMB composed of Dr. Ross Simp son, an 
epidemiologist, a biostatistician and one or more clinical researchers. The DSMB will review 
AEs every 6 months whereas the medical monitor will review AEs in real time and make 
decisions as of participant’s continuation of the clinical trial. The PI will review AEs weekly 
with research team  and may request additional review by Co -I on a case -by-case basis.  The 
medical monitor will  also be present at weekly meeting s in order to discuss/explain any event(s) 
that may occur.  
 
Every 6 months DSMB will review blinded AE reports, scores from suicide questio nnaires and 
any cognitive changes. If there is reason to view unblinded information, the DSMB will directly 
receive the list of participants’ identification numbers from Kristin Sellers.  Participant 
identification number will be displayed in a table accor ding to the three arms of the study; 
however the specific treatment of that arm will not be disclosed.  This will allow the DSMB to 
compare the three treatment groups.  
 
Reasons for stopping the study and asking for further investigation include; increase d suicide 
risk due to treatment (>25% of participants asked to seek mental health care), decrease in 
cognitive abilities based on baseline and end of study data  (>25% decrease in  scores in  >15% of 
participants) .  In addition, as mentioned above, if a seizure  occurs during a study visit, the 
clinical trial will be temporarily be placed on hold for further investigation.   
 
 
  
43 
 10 CLINICAL MONITORI NG 
The Purpose of the monitoring plan is to present the Frohlich Lab’s approach to monitoring 
clinical trials.  The plan facilitates compliance with good clinical practice.  
 
(a) The rights and well -being of human subjects are protected.  
(b) The reported trial data are accurate, complete, and verifiable from source documents.  
(c) The conduct of the trial is in complian ce with the currently approved protocol/amendment(s), 
with GCP, and with applicable regulatory requirement(s).  
 
This section identifies key monitoring activities and specifies the data to be reviewed over the 
course of a clinical trial.  This is a single site, investigator initiated, clinical trial so there will be 
no site monitoring plan in place.  
 
10.1 Frohlich Lab Monitoring Plan  
 
The latest version of the approved IRB application for this clinical trial will be followed at all 
times. This responsibilit y falls in the hands of the study coordinator and research assistants.  If at 
any time there is a deviation from protocol, the deviation from protocol log ( Appendix O ) will be 
filled out.  All team members will be trained on how and when to use this log.  The most up to 
date IRB application will be on file at the Clinical Trials desk in Rm 4109 of the NRB. 
Deviations will be sent to IRB every 4 -6 weeks (if necessary).  
 
At the end of the month clinical trials meeting with the PI, 3 randomly selected informed  consent 
forms will be chosen. The PI will verify  that (1) these forms have been filled out appropriately, 
and (2) the consent form process described in the SOP was followed and properly documented.  
Should any consent form be in violation, the research te am will perform and document a 
complete review of all consent forms.  
 
AE and SAE are clearly defined in the Master Protocol.  Documents of AE and SAE can be 
found in the study binder on file at the Clinical Trials desk in Rm 4109 of the NRB.  It is 
respons ibility of the study coordinator to report all events to the PI.  In all weekly meetings with 
the PI, all AE and SAE are discussed.  For our practices we have adapted the decision tree 
provided by UNC -CH IRB to assist with reporting of such events ( Attachm ent 1 ).  
 
At all weekly clinical trial team meetings, the study coordinator will chose one CRF and Source 
Document to assess  for completion and maintenance. At weekly clinical trials meeting, with the 
PI will assess completeness of data on REDCap (data sit e). The PI has read -only access.  This 
allows the PI to view reports that provide information on any missing data on an individual 
participant basis, but does not allow them to add, change or input any data.  
44 
 11 STATISTICAL CONSIDER ATIONS  
11.1 Study Hypothe ses 
 
11.1.1 Primary Objective  
 
Null hypothesis: There is no difference baseline and the 4  week follow up in MADRS 
score between treatment groups.  
 
Alternative hypothesis: There is a difference between baseline a nd the 4  week follow up 
MADRS score between t reatment groups.   
 
11.1.2 Secondary Objective  
 
Null hypothesis: There is no difference in changes of alpha frequency power between  
baseline EEG and EEG at completion of stimulation between treatment groups.  
 
Alternative hypothesis: There is a difference in  changes of alpha frequency power 
between  baseline EEG and EEG at completion of stimulation between treatment groups.  
 
11.2 Sample Size Considerations  
 
This clinical trial represents  a pilot study.  A pilot study is a clinical trial that is conducted to 
decide whether a new treatment should be tested in a large controlled trial therefore we do not 
calculate sample size.  It is difficult to recruit a large number of patients diagnosed with MDD to 
participate in a single site extensive study.  However, we exp ect with 20 participants in each 
group that we have enough power to detect significance if there is a clear effect of tACS on 
depression  and/or the underlying biomarkers .   
 
11.3 Final Analysis Plan  
 
We will perform spectral analysis of resting state EEG b efore and after stimulation treatment and 
use a mixed ANOVA with the within subject factor sessi on (day one of stimulation and 4  week 
follow up) and between subject factor treatment (sham, 10Hz tACS or 40Hz tACS). Spectral 
analysis will be performed with m ulti-tapered estimation of the frequency spectrum followed by 
integration over the classical alpha EEG band (8 -12 Hz).  We will apply the same statistical 
analysis procedure for o ur primary outcome of MADR scale . 
 
We will also use post -hoc paired or unpair ed Student’s t -test to identify the group or groups that 
differed. We will further control for multiple comparisons by using Bonferroni corrections.  
45 
 12 SOURCE DOCUMENTS AND ACCESS TO SOURCE  
DATA/DOCUMENTS  
Partners Human Research Committee (IRB):  
 All IRB C orrespondences are on file . 
 The study staff is IRB approved prior to performing any study procedures . 
 Adverse events and deviations are reported to IRB per current guidelines . 
 All versions of the IRB protocols and informed consent forms are on file . 
 
Infor med Consent:  
 Ensure that participant identification is on all pages of the ICF  
 There is documentation that the participant is given a copy of the consent form (Appendix C)  
 The participant and study representative signed and dated the consent form for him/h erself.  
 The participant initialed and dated all appropriate pages on the informed consent form.  
 Note to file (Appendix G) made for any informed consent deviations.   
 Ensure a valid (current version date) copy of the consent form was used . 
 
Protocol:  
 Conf irm that the study staff is conducting the study in compliance with the protocol approved 
by IRB  
 The protocol deviations (exceptions and violations) are documented in the participant chart and 
reported to IRB as required.  
  
Source Documents:  
 Each particip ant binder will contain a checklist to ensure that each binder has each source 
document. The checklist will be dated by the researcher for each time an assessment is 
administered. (Appendix P)  
 Review participant charts to ensure the accuracy, completeness and legibility of the data  
 Any correction made to the source documents is dated, initialed, and explained. The original 
entry should not be obscured.  
 The protocol specific source documents are on file.  
 Source documents are completed in ink . 
 Note to files  (Appendix G) are made for missing or incomplete data and to explain any 
discrepancies or additional comments.  
 
Electronic Case Report Forms (eCRF)  
 Ensure the data reported on the eCRF is consistent with the source documents.  
 Discrepancies between the s ource documents and eCRF are explained in a note to file 
(Appendix G) or captured in a comment in the eCRF.  
46 
   
DNA  
 Participant names will not be on any of the samples collected at the initial session . DNA testing 
is performed with in the University of Nort h Carolina  at Chapel Hill and the samples are not 
shared with or processed by any third party  outside the university . 
 
The research coordinator, research assistant s, and PI will have access to all of the above 
information .  CO -I and medical monitor  will ha ve access to files upon request as they will need 
access to the locked room s and filing cabinets in which these documents are located.  The key 
linking dummy identifiers with subject information will be securely destroyed after completion 
of data acquisiti on. 
 
 
47 
 13 ETHICS/PROTECTION O F HUMAN PARTICIPANTS  
13.1 Ethical Standard  
 
The investigator will ensure that this study is conducted in full conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection o f Human 
Subjects of Research, as drafted by the US National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR Part 
46 and/or the ICH E6; 62 Federal Regulations 25691 (1997).  
 
13.2 Institutional Review Board  
 
The Office  of Human  Research  Ethics  is responsible for ethical and regulatory oversight of 
research at UNC -Chapel Hill that involves human participants. The OHRE administers, supports, 
and guides the work of the Institutional Re view Boards and all related activities. Any research 
involving human participants proposed by faculty, staff, or students must be reviewed and 
approved by an IRB before research may begin, and before related grants may be funded. OHRE 
and the IRBs are crit ical components of the coordinated Human Research Protection Program, 
which serves to protect the rights and welfare of human participants. All components of this 
program must work together to ensure institutional compliance with ethical principles and 
regulatory requirements. The following is a mission statement for the coordinated Human 
Research Protection Program:  
 
The University  of North  Carolina  at Chapel  Hill is committed  to expanding  and disseminating  
knowledge  for the benefit  of the people  of North  Carolina  and the world.  An important  part of 
that commitment  to knowledge  is research  of the highest  quality  on all aspects  of the health  and 
behavior  of people,  and such research  is only possible  through  the participation  of humans  as 
research  participant s. Human  participants  are partners  in research  and a precious  resource  to the 
university.  At UNC -Chapel  Hill, human  participant  research  is a privilege,  but not a right.  
Consistent  with that philosophy,  it is the mission  of the UNC -Chapel  Hill Human  Resear ch 
Protection  Program  to ensure  that 
 
1. The rights  and welfare  of human  participants  are paramount  in the research  process;  
2. The highest  standards  of ethical  conduct  are employed  in all research  involving  human  
participants;  
3. Research  investigators  are properl y trained  in the ethical  and regulatory  aspects  of 
research  with human  participants;  
4. Research  investigators  deal honestly  and fairly  with human  participants,  informing  them  
fully  of procedures  to be followed,  and the risks  and benefits  of participating  in research;  
and 
48 
 5. Research  using  human  participants  at UNC -Chapel  Hill conforms  to all applicable  local,  
state,  and federal  laws and regulations  and the policies  of the university.  
 
13.3 Informed Consent Process  
 
Informed consent is a process that is initiated  prior to the individual’s agreeing to participate in 
the study and continues throughout the individual’s study participation.  Extensive discussion of 
risks and possible benefits of tACS will be provided to the participants and their families. 
Consent for ms describing, in detail, the study intervention, device, procedures, and risks are 
given to the participant and written documentation of informed consent is required prior to the 
administration of any treatment or assessments used in this study.  Please s ee Appendix C for an 
example of the Documentation of Informed Consent Process form. All consent forms will be 
IRB-approved and updated with any new information as modifications are made throughout the 
study  (Appendix D) . 
 
Together, the researcher and poten tial participants will review the clinical trial in its entirety. At 
several intervals during the consent review, the researcher will ask the participant questions that 
will assess the comprehension of the information in the consent. If the participant is unsure or 
does not know, the researcher will return to that section and more carefully explain the 
information. Participant s must sign the informed consent document prior to any procedures 
taking place.  If needed, the participants will have the opportunit y to discuss the study with their 
surrogates or think about it prior to agreeing to participate.  Participants may withdraw consent at 
any time throughout the course of the trial.  A copy of the signed informed consent document 
will be given to the partici pants for their records.  The rights and welfare of the participants will 
be protected by emphasizing to them that the quality of their medical care will not be adversely 
affected if they decline to participate in this study.  
 
13.4 Exclusion of Women, Mino rities, and Children (Special Populations)  
 
Non-English speaking individuals are excluded because the ability to accurately and completely 
communicate study information, answer questions about the study, and obtain consent is 
necessary.  Female participants  will be asked if there is any reason to believe they might be 
pregnant. Pregnant participants will be excluded despite the fact that theoretical risk to mother or 
fetus is exceedingly small, since no safety data for pregnancy is known to exist for transcr anial 
current stimulation studies. All women of child -bearing potential will be asked to take a 
pregnancy test during the initial session in order to determine eligibility for the study.  
49 
 13.5 Participant Confidentiality  
 
Participant confidentiality is stri ctly held in trust by the participating investigators, their staff, 
and the research team.  This confidentiality is extended to cover testing of biological samples and 
genetic tests in addition to the clinical information relating to participants.  
 
All dat a will only be referenced by dummy identifier code. Data will be stored on a password 
protected computer. A key connecting names and code numbers will be kept in a locked cabinet, 
accessible only by research personnel. All data will be stored and analyzed on password 
protected computers, also only accessible by research personnel. Participants will not be 
identified in any report or publication about this study . 
 
13.6 Study Discontinuation  
 
In the event that the study is discontinued , participants who have completed or who are still 
enrolled in the study will be notified.  A ny new information gained during the course of the study 
that might affect participant’s willingness to continue will be communicated within 2 days of the 
PI learning this information.  
50 
 14 DATA HANDLING AND R ECORD KEEPING  
The study coordinator and research assistants are responsible for the accuracy, completeness, 
legibility, and timeliness of the data reported. During weekly meetings, the data will be reviewed 
by the PI to check for comple teness and continued safety of the participants and research staff.  
Any changes made to the data will involve crossing out the original data, documenting the new 
data with the initials and date of the researcher making the change.  
 
14.1 Data Management R esponsibilities  
 
The responsibilities designated to each member of the research team are documented on the 
Delegation of Authority SOP  (Appendix N ).  The study coordinator and research assistants will 
be responsible for the informed consent process, review  for eligibility, questionnaire 
administration, data entry, device administration, EEG administration, and CRF entries. The 
study coordinator will be responsible for AE/SAE documentation and reporting, while the PI will 
be responsible for the AE assessment , review of the AE documentation forms and overview of 
the research staff. Dr. Asa Cordle will be the medical monitor for the study.        
 
REDCap will serve as a secure data management tool for this study. The study coordinator and 
research assistants wi ll have complete access to the REDCap system, while the PI and Co -I will 
have read only ability. This will enable the researchers to enter the data and the PI and Co -I to 
review.  
 
14.2 Data Capture Methods  
 
Clinical data (including AEs, concomitant medicat ions, and expected adverse reactions data) and 
clinical laboratory data will be entered into a data capture system provided by REDCap.  The 
data system includes password protection and internal quality checks, such as automatic range 
checks, to identify da ta that appear inconsistent, incomplete, or inaccurate.  Clinical data will be 
entered directly from the source documents.  
 
14.3 Types of Data  
 
Data will be collect ed to determine eligibility. During the initial  session, the MINI,  and the 
HDRS17 will be ad ministered. In order to participate in this study, the participant must have a 
diagnosis of MDD (unipolar, non -psychotic), have a low suicide risk, and  have a score of greater 
than 8  on the HDRS.  
 
We will also be collecting data to assess cognitive abilit ies at baseline and endpoint (5 week 
follow up). The MOCA and n-back working memory task will be administered as two separate 
51 
 measurements of cognition.   
 
The Suicide Assessment and the YMRS will be administered at the beginning of each session to 
monitor  the safety of the participant. The Suicide Assessment will be administered in order to 
evaluate whether the participant has experienced any SI or SB in the past 24 hours. The YMRS 
will assess the development of any manic symptoms throughout the study. The  stimulation 
adverse effects questionnaire will be administered after each stimulation session in order to 
monitor any side effects the participant may experience from the stimulation treatment.  
The MADRS will be our primary outcome for this study. We wil l administer this questionnaire 
on the 1st day of stimulation, the 5th day of stimulation, and the 2 and 4  week follow up. As our 
primary outcome, the data we collect with the MADRS will be used to determine effectiveness 
of treatment.  
 
The HDRS17  will be  used not only to determine  eligibility, but also  to collect additional data 
throughout the study. This questionnaire will also be administered on the 1st day of stimulation, 
the 5th day of stimulation, a nd the 2 and 4  week follow up, in addition to during  the initial 
session.  
 
The remainder of the assessments will collect data to monitor depressive symptoms throughout 
the study, as extra safety assessments. The BDI (Attachment 1) and CGI (Attachment 3) will be 
administered the 1st day of stimulation, the 5th day of stimulation, and at the 2 and 4  week follow 
ups. An EEG will be administered the 1st day of stimulation, the 5th day of sti mulation and at the 
end of the 4  week follow up session. The EEG data will enable assessment of neurophysiological 
changes  induced by stimulation.  
 
14.4 Timing/Reports . 
 
The stimulation adverse effects questionnaire will be administered at the end of each stimulation 
session. Any AE will be reported to the PI within 72 hours  and medical monitor within 24 hours . 
 Reports will  be run at the end of each week and any unusual  activity that could be a cause of 
concern will be reported to the PI at weekly meetings .  
 
14.5 Study Records Retention  
 
According to the University of North Carolina at Chapel Hill’s Archives and Record 
Mana gement Services schedule for General Records Retention and Disposition Schedule 6.10, 
records will be kept for 5 years after the completion of the study or grant end date, whichever is 
later.  
 
52 
 14.6 Protocol Deviations  
 
All deviations from the protocol wil l be addressed in study participant source documents. The 
researcher will complete a Protocol Deviation Log (Appendix O) using the participant code as the 
identifier. This form will collect information such as the date the deviation occurred, details of 
what the deviation consisted of, any corrective and preventative actions that were taken as a 
result of the deviation, and the date that the PI and IRB were notified. The PI will review the 
information and initial once approved.  A completed copy of the Prot ocol Deviation Form will be 
maintained in the regulatory file, as well as in the participant’s source document.  Protocol 
deviations will be sent to the IRB per their guidelines.  The site PI/study staff will be responsible 
for knowing and adhering to thei r IRB requirements.  
53 
 15 PUBLICATION POLICY  
This study will be registered on clinicaltrials.gov once IRB approved. There are no restrictions 
on publications since this is an investigator -initiated study funded by a grant ag ency (NARSAD) 
that has no influence  on the publications resulting from this study. The aim is to publish  the 
results of this study in a peer -reviewed, highly -ranked psychiatry journal.  
54 
 16 LITERATURE REFERENC ES 
 
Ali, M.M., Sellers, K.K., and Frohlich, F. (2013). Transcranial alternating curr ent stimulation 
modulates large -scale cortical network activity by network resonance. J Neurosci 33, 11262 -
11275.  
 
Antal, A., Chaieb, L., Moliadze, V., Monte -Silva, K., Poreisz, C., Thirugnanasambandam, N., & 
... Paulus, W. (2010). Brain -derived neurotrop hic factor (BDNF) gene polymorphisms shape 
cortical plasticity in humans. Brain Stimulation, 3(4), 230 -237. doi:10.1016/j.brs.2009.12.003  
 
Beck, A. T., Steer, R. A., & Garbin, M. G. (1988). Psychometric properties of the Beck 
Depression Inventory: Twenty -five years of evaluation. Clinical Psychology Review, 8(1), 77 -
100. doi:10.1016/0272 -7358(88)90050 -5 
 
Berlim, M.T., Van den Eynde, F., and Daskalakis, Z.J. (2013). Clinical utility of transcranial 
direct current stimulation (tDCS) for treating major depress ion: a systematic review and meta -
analysis of randomized, double -blind and sham -controlled trials. Journal of psychiatric research 
47, 1 -7.  
 
Brunoni, A.R., Teng, C.T., Correa, C., Imamura, M., Brasil -Neto, J.P., Boechat, R., Rosa, M., 
Caramelli, P., Cohen , R., Del Porto, J.A. , et al. (2010). Neuromodulation approaches for the 
treatment of major depression: challenges and recommendations from a working group meeting. 
Arq Neuropsiquiatr 68, 433 -451.  
 
Brunoni, A.R., Valiengo, L., Baccaro, A., Zanao, T.A., de  Oliveira, J.F., Goulart, A., Boggio, 
P.S., Lotufo, P.A., Bensenor, I.M., and Fregni, F. (2013). The sertraline vs. electrical current 
therapy for treating depression clinical study: results from a factorial, randomized, controlled 
trial. JAMA Psychiatry 7 0, 383 -391.  
 
Dozois, D. A., Dobson, K. S., & Ahnberg, J. L. (1998). A psychometric evaluation of the Beck 
Depression Inventory –II. Psychological Assessment, 10(2), 83 -89. doi:10.1037/1040 -
3590.10.2.83  
 
Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A. , et al. 
(2003). The BDNF val66met polymorphism affects activity -dependent secretion of BDNF and 
human memory and hippocampal function. Cell, 112(2), pp. 257 –269.  doi:10.1016/S0092 -
8674(03)00035 -7 
Frohlich, F ., & McCormick, D. A. (2010). Endogenous electric fields may guide neocortical 
network activity.  Neuron,  67(1), 129 -43.  
 
Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & 
Weinberger, D. R. (2003). Brain -Derived Neurotrophic Fa ctor val⁶⁶ met Polymorphism Affects 
55 
 Human Memory -Related Hippocampal Activity and Predicts Memory Performance. The Journal 
Of Neuroscience, 23(17), 6690 -6694 . 
 
Henriques, J.B., and Davidson, R.J. (1990). Regional brain electrical asymmetries discriminate 
between previously depressed and healthy control subjects. J Abnorm Psychol 99, 22 -31.  
 
Herrmann, C.S., Rach, S., Neuling, T., and Struber, D. (2013). Transcranial alternating current 
stimulation: a review of the underlying mechanisms and modulation of cog nitive processes. 
Front Hum Neurosci 7, 279.  
 
Kalu, U.G., Sexton, C.E., Loo, C.K., and Ebmeier, K.P. (2012). Transcranial direct current 
stimulation in the treatment of major depression: a meta -analysis. Psychol Med 42, 1791 -1800.  
 
Khan, A., Khan, S. R., Shankles, E. B., & Polissar, N. L. (2002). Relative sensitivity of the 
Montgomery -Asberg Depression Rating Scale, the Hamilton Depression rating scale and the 
Clinical Global Impressions Rating Scale in antidepressant clinical trials. International Clinica l 
Psychopharmacology, 17(6), 281 -285. doi:10.1097/00004850 -200211000 -00003  
 
Kleim, J. A., Chan, S., Pringle, E., Schallert, K., Procaccio, V., Jimenez, R., & Cramer, S. C. 
(2006). BDNF val66met polymorphism is associated with modified experience -dependent 
plasticity in human motor cortex. Nature Neuroscience, 9(6), 735 -737. doi:10.1038/nn1699  
  
Laufs, H., Krakow, K., Sterzer, P., Eger, E., Beyerle, A., Salek -Haddadi, A., and Kleinschmidt, 
A. (2003). Electroencephalographic signatures of attentional and cogn itive default modes in 
spontaneous brain activity fluctuations at rest. Proc Natl Acad Sci U S A 100, 11053 -11058.  
 
Leentjens, A. G., Verhey, F. J., Lousberg, R., Spitsbergen, H., & Wilmink, F. W. (2000). The 
validity of the Hamilton and Montgomery -Åsberg  depression rating scales as screening and 
diagnostic tools for depression in Parkinson's disease. International Journal Of Geriatric 
Psychiatry, 15(7), 644 -649. doi:10.1002/1099 -1166(200007)15:7&lt;644::AID -
GPS167&gt;3.0.CO;2 -L 
 
National Institute of Heal th. (2011). Further resources for NIH grantees. Retrieved from: 
http://grants.nih.gov/clinicaltrials_fdaaa/definitions.htm  
Palva, S., and Palva, J.M. (2007). New vistas for alpha -frequency band oscillations. Trends in 
neurosciences 30, 150 -158. 
Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., Egan 
M.F., Meyer -Lindenberg A, Weinberger D.R. (2004 ). “The Brain -Derived Neurotrophic Factor 
val66met Polymorphism and Variation in Human Cortical Morphology.” The Journal of 
Neuro science 24 (45): 10099 –102. doi:10.1523/JNEUROSCI.2680 -04.2004.  
Sheehan, D. V., Lecrubier, Y., Sheehan, K., Amorim, P., Janavs, J., Weiller, E., & ... Dunbar, G. 
C. (1998). The Mini -International Neuropsychiatric Interview (M.I.N.I): The development and 
56 
 validation of a structured diagnostic psychiatric interview for DSM -IV and ICD -10. Journal Of 
Clinical Psychiatry, 59(Suppl 20), 22 -33. 
Williams, J. W. (2001). Standardizing the Hamilton Depression Rating Scale: past, present, and 
future. European Archives O f Psychiatry And Clinical Neuroscience, 251(Supl2), 6 -12. 
doi:10.1007/BF03035120  
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978). A rating scale for mania: 
Reliability, validity and sensitivity. The British Journal Of Psychiatry, 133429 -435. 
doi:10.1192/bjp.133.5.429  
 
 
 ________________________________ ________________________________ ____________________________   
57 SUPPLEMENTS/APPENDIC ES 
APPENDIX A: SCHEDULE  OF EVENTS  
A detailed schematic describing all visits and assessments.  
 MDD Study Outline  
Procedures  Initial Session  Day 1 of 
Stimulation  Days 2 –4 of 
Stimulation  Day 5 of 
Stimula tion Week 2  
Follow Up  Week 4  
Follow Up  
Signed Consent Form  X      
Assessment of Eligibility 
Criteria  X      
Demographics  X      
Medications  X      
BDNF test  X      
MINI  X      
HDRS  X X  X X X 
 YMRS   X X X X X 
Suicide Assessment   X X X X X 
MADRS   X  X X X 
BDI  X  X X X 
CGI  X  X X X 
MOCA   X    X 
n-back  working memory   X  X  X 
Stimulation   X X X   
EEG  X X  X  X 
Stimulation Adverse 
Events Questionnaire   X X X  X 
       
 
 
 
 ________________________________ ________________________________ ____________________________   
58 APPENDIX B: STUDY START UP CHECKLIST  
 
Study Start Up Checklist  
Study  Title: ______________________________________________________    
 
Funding Source: 
___________________________________ ____________________________  
 
 Date Completed   
CRMS Recorded Created  ______________________   
IRB Application Submitted  ________________ ______  Approved 
Date : 
___________  
CVs/Certifications/Medical 
License  ______________________   
IRB Roster  ______________________   
IRB Statement of Compliance  ______________________   
PI Signature of Protocol  ______________________   
HD-974 Forms  ________ ______________   
                                                                Date Completed  
Study Binders Created  ______________________  
______________________  
______________________  
______________________  
______________________  
______________________  
______________________  
______________________  
______________________  
 
 
 
______________________  
______________________  
______________________  
______________________  
 Regulatory Documents Filed  
Protocol Deviation Tracking Log 
Filed  
Completion of Site T raining, 
Filed  
Delegation Log Completed  
Develop Recruitment Plan  
Begin Pre -Screening  
Source Documents Created  
Participant Folders Created  
 
 
 
Schedule Study Start Up 
Meeting  
Lab Kits Received  
Participant Supplies Received  
Investigat ional Device Received  
 
 
 ________________________________ ________________________________ ____________________________   
59  
APPENDIX C: DOCUMENTATION OF INFORMED CONSENT PROCESS  
Abbreviated Study Title:       
 
Participant Name :     ____       Date of Birth:      
 
Medical Record #: __________________________  
 
Please INITIAL  next to “Yes” or “No ” by ea ch line as appropriate (if “No,” an explanation MUST be 
provided in the notes section below ). 
 
 Yes  No Participant and/or the participant’s legally authorized representative (LAR) 
was given a copy of the consent document to read.  
 Yes  No Ample time was p rovided for reading the consent document, and the 
participant (or participant’s LAR) was encouraged to ask questions.  
 Yes  No All questions and concerns were addressed to the satisfaction of the 
participant (or participant’s LAR) prior to signing the cons ent document.  
 Yes  No The PI or CO-I was available for questions prior to the subject signing the 
consent.  
 Yes  No The subject (or subject’s LAR) agreed to participate in the study and 
signed/dated the consent document.  
 Yes  No A copy of the signed con sent document was provided to the participant (or 
participant’s LAR).  
     Verbal consent was obtained (per IRB approved consent process).  
Documentation of the process and the individual(s) witnessing the process is 
described below.  
 Yes  No No procedure s specifically related to the study were performed prior to the 
participant signing the consent document.  
 
The details of this research study were discussed with the participant (or participant’s LAR), including an 
explanation of all of the elements of the  consent document.  The IRB -approved consent document was 
signed and dated by the participant (or participant’s LAR) and a copy of the signed consent document 
was placed in the participant’s medical record (unless otherwise noted).  No activities specifica lly related 
to the research were initiated until after the execution of the consent document.  The principal 
investigator was notified of the participant’s consent to be enrolled in the study and agrees with 
enrollment of subject.  
 
The participant (or part icipant’s LAR) signed consent document version  ______________ on 
 ________________________________ ________________________________ ____________________________   
60     (date)  at   (time) . 
 
Notes :             
             
             
             
             
             
              
 
              
Signature of Person Obtaining Consent    Date     Time  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ________________________________ ________________________________ ____________________________   
61 APPENDIX D: CONSENT AMENDMENT TRACKING LOG  
Study Title:  
 
 
 
Change Initiated 
by: Adjustments made  
to consent form   Date 
Submitted 
to IRB  Date of 
IRB 
Answer  Requires 
Stipulations? 
(Y/N)  Stipulation 
Submission 
Date  IRB 
Approval 
Date  
Initials  Reference 
ID 
        
        
        
        
        
        
        
        
        
        
        
        
        
 ________________________________ ________________________________ ____________________________   
62 APPENDIX E: INFORMED CONSENT EVALUATION FEEDBACK  
 
Name of Research Study:  
 
 
You have been asked to be in a research  study. This sheet will help you think 
of questions to ask  but you may have other questions.  This is not a test.  We 
want to be sure you understand what it means to be in this research study.  
You should understand the research  before you decide whe ther or not to 
participate . 
 
 
1. What is the purpose  of the research?  
 
 
2. What are the possible benefits  of the research?  
 
 
3. What are the possible risks of the research?  
 
 
4. Will everyone receive the same treatment?  
 
 
5.   How is this research different than the c are or treatment I would get if I wasn ’t in 
the research study ?  
 
 
6.  Does  in the research cost me anything extra?  
 
 
7. Can you  stop being in the re search once you’ ve started?  
 
 
8.  Who will view your medical  records?  
 
 
9. Who do you  call if I have questions about  being a research subject?  
 
10.  Any questions? 
 ________________________________ ________________________________ ____________________________   
63 APPENDIX F: IRB AMMENDMENT TRACKING LOG  
Study Title:   
 
 
 
Change Initiated by:  Description of IRB: Type and Brief Summary  Date 
Submitted 
to IRB  Date of 
IRB 
Answer  Requires 
Stipulations? 
(Y/N)  Requires 
Update d 
Consent 
Form? 
(Y/N)  Stipulation 
Submission 
Date  IRB 
Approval 
Date  
Initials  Reference 
ID 
         
         
         
         
         
         
         
         
         
         
         
         
         
 ________________________________ ________________________________ ____________________________   
64 APPENDIX G: NOTE TO FILE  
 
IRB#: 14 -1622         PI: Flavio Frohlich  
Study Title: 
________________________________________________________________  
Date of Occurrence: ________________  
Research Name: ____________________________________  
Participant ID: _________________  
Reason for N ote: 
________________________________________________________________ 
________________________________________________________________  
Note: 
______________________________________________________________________
_____________________________________________ _________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
_____________________ _________________________________________________
______________________________________________________________________
______________________________________________________________________
___________________________________________________________________ ___
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
___________________________________________ ___________________________  
 
Corrective action (if applicable): 
______________________________________________________________________ 
______________________________________________________________________
___________________________________________________ ___________________
______________________________________________________________________  
 
Signature: ______________________________       Date: _______________  
 
 
 ________________________________ ________________________________ ____________________________   
65 APPENDIX H: INCLUSION/EXCLUSION CRITERIA CHECKLIST 
(WITH PI SIGNATURE FOR PARTICIPANT ELIGIBI LITY)  
 
Participant ID: ____________________________  Date: ____________  
 
Inclusion Criteria  
Ages 18 -65 years           Yes   No 
DSM -IV diagnosis of MDD; unipolar, non -psychotic       Yes   No 
Hamilton Rating D epression Rating Scale score >8       Yes   No 
Low suicide risk                                                                                                                                Yes                No  
If the responses to all the inclusion criteria are YES and all the exclusion criteria are NO, the 
participant is able to participate in the trial.  
Is the participant eligible to participate in th e trial?    YES   NO 
If NO, discontinue subject.  
If YES, I have reviewed the inclusion and exclusion criteria and have determined that the 
participant is eligible for participation in the trial.  
 
Investigator Signature: ____________________________    Date: _____________  
 Exclusion Criteria  
DSM -IV diagnosis of alcohol of substance abuse (other than nicotine)   
within the last month or a DSM -IV diagnosis of alcohol or substance      Yes   No 
dependence (other than nicotine) within the last 6 months  
Medical or neurological illness (unstable cardiac disease, AIDS,  
malignancy, liver or renal impairment) or treat ment for a medical disorder     Yes   No 
that could interfere with study participation  
History of traumatic brain injury, reoccurring seizures or later cognitive      Yes   No 
rehabilitation or causing cognitive sequelae  
Prior brain surgery            Yes   No 
Any brain devices/implants, including cochlear implants and aneurysm clips     Yes   No 
Co-morbid neurological condition (i.e. seizure disorder, brain tumor)      Yes   No 
Non English speakers            Yes   No 
Pregnancy, nursing, or if female and  fertile, unwilling to use       Yes   No 
appropriate birth control measures during study participation  
Capacity to understand all relevant risks and potential       Yes   No 
benefits of the study (informed consent)  
Current axis I mood, psychotic disorde r other than MDD  
Lifetime comorbid psychiatric bipolar or psychotic disorder  
Eating disorder (current or with the past 6 months)  
Obsessive -compulsive disorder (lifetime)  
PTSD (current or with the past 6 months)  
ADHD (current or with the past 6 months)  
Current use of benzodiazepines and/or antiepileptic drugs  
 ________________________________ ________________________________ ____________________________   
66 APPENDIX I: TELEPHONE CONTACT LOG  
 
Protocol Title: ___________________________________________             Subject #: ______________________  
 
 
Date/Time  
  
Incoming/Outgoing   
Message/Conversation   
Reason for calling   
Comments/Researcher Initi als 
 
 
  
Incoming  
Outgoing  
  
Message  
Conversation    
  
Incoming  
Outgoing  
  
Message  
Conversation    
  
Incoming  
Outgoing  
  
Message  
Conversation    
  
Incoming  
Outgoing  
  
Message  
Conversation    
  
Incoming  
Outgoing  
  
Message  
Conversation    
  
Incoming  
Outgoing  
  
Message  
Conversation    
 ________________________________ ________________________________ ____________________________   
67 APPENDIX J: ADVERSE EVENTS  TRACKING LOG  
 
 
Participant ID   
 if AE meets 
definition of 
serious*   
Was this an 
Expected or 
Unexpected 
Event?   
Grade / Intensity  
 
1. Asymptomatic  
2. Mild  
3. Moderate  
4. Severe  
  
Date of 
Incident   
Rela tionship 
to study 
device  
 
1. Related  
2. Possibly  
3. Not Likely  
4. Not Related  
  
Was 
Action 
Taken?  
 
 
 
  
Action(s) Taken:  
 
  
Outcome:  
 
1. Recovered  
2. Not Recovered  
3. Recovered 
w/Sequel  
4. Fatal  
5. Unknown   
PI Initials / 
Date  
  Expected/  
Unexpected     Yes  /  
No    
  Expected/  
Unexpected     Yes  /  
No    
  Expected/  
Unexpected     Yes  /  
No    
  Expected/  
Unexpected     Yes  /  
No    
  Expected/  
Unexpected     Yes  /  
No    
  Expected/  
Unexpected     Yes  /  
No    
  Expected/  
Unexpected     Yes  /  
No    
  Expected/  
Unexpected     Yes  /  
No    
  Expected/  
Unexpected     Yes  /  
No    
  Expected/  
Unexpected     Yes  /  
No    
 ________________________________ ________________________________ ____________________________   
68 APPENDIX K: UNEXPECTED/SERIOUS ADVERSE EVENT TRACKING LOG  
 
 
Participant ID  
  
  
Date Event 
Occurred   
Was this an 
Expected or 
Unexpecte d 
Event?   
Date Study 
Team Notified 
of Event  
  
Event  
  
Date Reported to 
IRB 
  
Study SAE Form 
Completed  
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
  Expected/  
Unexpected     Yes     No      
N/A      
 ________________________________ ________________________________ ____________________________   
69 APPENDIX L: ADVERSE EVENT REPORT FORM  
 
Adverse Effects Report:  
Reasons for Report (adverse event, time, date and place of occurrence if 
available):  
1. What do we already know about the therapy?  
a)  
2. What is the temporal relationship of the AE to the study therapy?  
a) 
3. Does the AE improve or disappear when the therapy is stopped?  
     a)  
4. Is the AE a worsening of baseline symptom(s)?  
        a) 
5. Is the AE a result of an underlying concurren t medical condition(s) or concurrent 
medication(s)?  
       a) 
6. Additional Information provided by research team  
      a) 
Research team member signature ______________________________________ 
Date____________  
 
Co-Investigator :  
__________________________ ____________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
___________________________________________ ___________________________  
 
Steps to be taken (if applicable)  
______________________________________________________________________
____________ __________________________________________________________
______________________________________________________________________
______________________________________________________________________
__________________________________________________________ __ 
CI signature 
_________________________________________ ______________Date___________  
 
PI Comments:  
______________________________________________________________________
______________________________________________________________________
 ________________________________ ________________________________ ____________________________   
70 ______________ ________________________________________________________
______________________________________________________________________
______________________________________________________________________
___________________________________________ _________________ __________  
 
Steps to be taken (if applicable)  
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
____________________________________________________________ __________  
 
PI signature 
_______________________ ___________________________ Date______________  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ________________________________ ________________________________ ____________________________   
71  
 
 
APPENDIX M: SERIOUS ADVERSE EVENT REPORT FORM  
 
Serious Adverse Event Form  
Participant ID: _______________  
 
1. Location of SAE (e.g., clinic, home): __________________________________________  
 
2.   Age: ______  
 
3.  Gender: Male Female  
 
4. SAE term (provide diag nosis): _____________________________________________________  
 
4a. If diagnosis is not known, symptoms: ____________________________________________  
 
5. Date of onset: ________________________ (dd/mm/yyyy)  
 
6. What is the severity grade of the serious adve rse event?  
 
Grade: 1: Mild  
Grade 2: Moderate  
Grade 3: Severe  
Grade 4: Life -threatening  
Grade 5: Death  
 
7. Did the participant receive the investigational product or study intervention prior to this SAE?  
   Yes   No   N/A 
 
7a. If yes, identify the investigational product or study intervention received prior to the SAE:  
Investigational Product/Study Intervention  
 
Dose_______  
Units_______  
Frequency________  
 
Start Date _____/_____/______ (dd/mm/yyyy)  
Stop Date _____/_____/______ ( (dd/mm/yyyy)  
Check  if Ongoing  
      8. Action taken with investigational product/study intervention:  
 
Continued  
Lowered  
Interrupted  
Discontinued  
Increased  
N/A 
 
9. Outcome of SAE:  
 
 ________________________________ ________________________________ ____________________________   
72 Ongoing at this time  
Resolved without sequelae  
Resolved with sequelae  
Death  
Present  at death, not contributing to death  
 
 
10. Date of resolution: ________________________ (dd/mm/yyyy) or  
 Ongoing at end of study  
 
11. Seriousness criteria? (Check all that apply)  
 
Life-threatening  
Required hospitalization or  
Prolongation of existing hospitalization  
Congenital anomaly  
Disabling/incapacitating  
Important medical event  
Fatal  
If fatal: 11a. Date of death: ________________________ (dd/mm/yyyy)  
11b. Primary cause of death: _______________________________________________  
11c. Was an autops y performed?  
 
Yes  
No 
 
12. Relationship to investigational product/study intervention:  
 
Related (Associated with the use of the study intervention. There is a reasonable 
possibility that the experience may have been caused by the study intervention.)  
Unrelated  
 
13. If SAE is unrelated to investigational product/safety intervention, select all possible etiologies:  
Concurrent illness, disease, or other external factors, specify:  
____________________________________________________________________________ _
_____________________________________________________________________________  
 
Concurrent medication, specify:  
_____________________________________________________________________________  
 
Secondary study procedure, specify: 
_____________________________ ________________________________________________  
 
Accident, trauma, or other external factors, specify: 
_____________________________________________________________________________  
 
Other, specify: 
_________________________________________________________ ____________________  
 
14. Did the participant receive any relevant concomitant medications in response to the SAE?  
Yes 
 No 
  14a. If yes, please specify: Name, Start and Stop date or On going  
 ___________________________________________________________ __________________  
 
 ________________________________ ________________________________ ____________________________   
73  
 
15. Did the participant receive any treatments/procedures in response to the SAE?  
 
Yes  
No  
 
15a. If yes, please specify  
 
_____________________________________________________________________________  
 
________________ _____________________________________________________________  
 
16. Did the participant receive relevant laboratory or diagnostic tests in response to the SAE?  
 
Yes  
No  
 
16a. If yes, provide the name of the test and results with normal ranges and/or suppl emental  
  exams below:  
 
____________________________________________________________________________  
 
____________________________________________________________________________  
 
___________________________________________________________________________ __ 
 
 
17. Narrative/Comments (provide a description of the serious adverse event including chronological 
clinical presentation and evolution of the serious adverse event and associated signs/symptoms):  
 
_____________________________________________________ _______________________________  
 
____________________________________________________________________________________  
 
____________________________________________________________________________________  
 
___________________________________________________ _________________________________  
 
____________________________________________________________________________________  
 
____________________________________________________________________________________  
 
_________________________________________________ ___________________________________  
 
____________________________________________________________________________________  
 
____________________________________________________________________________________  
 
_______________________________________________ _____________________________________  
 
____________________________________________________________________________________  
 
____________________________________________________________________________________  
 
 ________________________________ ________________________________ ____________________________   
74  
18. Completion of form: printed names, signa tures and date of signature  
 
Person Completing Form 
(print name)             Person Completing Form  
                   (signature)  Date  
   
______________________________________________________________________________  
 
Investigator (print name)  Investigator (signature)  Date  
 
______________________________________________________________________________  
 ________________________________ ________________________________ ____________________________   
75 APPENDIX N: DELEGATION OF AUTHORITY  
 
  USE ONE VERTICAL COL UMN FOR EACH DESIGNE E 
Designee (full 
name)  Courtney 
Lugo  Juliann Mellin  Dr. Asa Cordle  Michael Boyle  Dr. David 
Rubinow  Dr. Flavio 
Frohlich  
Title & Position        
Delegated Activity  
(see codes)        
Designee 
Signature & Dates        
Designee Initials 
(signed)        
 Activity Codes:  
01:  Informed Consent                                 04:  CRF Entries                           07:  Data Entry  
02:  Initial Session Review for Eligibility   05:  Device Administration           08: Adverse Event Assessment  
03:  Questionnaire Administration              06:  EEG Administration              09: Adverse Event 
Documentation/Report ing 
10: Medical Monitor   
 Investigator’s Authorization:  I hereby delegate the above significant research -related duties to the following 
persons and understand that the overall responsibility for conduct of the research remains with me.  
 
1Investigator’s Signature:  Date:  
 ________________________________ ________________________________ ____________________________   
76 APPENDIX O: PROTOCOL DEVIATION LOG  
 
 
Participant ID   
Date Occurred   
Description   
CAPA*   
Date PI Notified   
Date IRB 
Notified   
PI Initial/Date  
       
       
       
       
       
       
       
 ________________________________ ________________________________ ____________________________   
77 APPENDIX P: ENROLLMENT LOG  
 
Subject ID  Date Consent 
Signed  Gender  Race  Ethnicity  Treatment 
Arm / 
Group  Explanation if subject did not complete 
study / Comment  
1   M  F      
2   M  F      
3   M  F      
4   M  F      
5   M  F      
6   M  F      
7   M  F      
8   M  F      
9   M  F      
10   M  F      
11   M  F      
12   M  F      
13   M  F      
14   M  F      
15   M  F      
 
 
 
 ________________________________ ________________________________ ____________________________   
78  
APPENDIX Q : TRAINING LOG  
Title of Training:______________________________   DATE:________ __________________  
(e.g., Protocol; Amendment; IRB [include version #/date])  
 
 
By signing below, each staff member verifies they have been trained on the information and understand the 
obligations/responsibilities associated with this training.  
 
Trainer Name (if relevant):_____________________________  
(Please print)  
Trainer Signature ( if relevant):___________________________________Training Date  
(if different than 
above)  Trainee Name  
(please print)  Trainee Signature  Training Format  
(ie Presentation; Self -Study)  
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
 APPENDIX R : PARTICIPANT OFF STUDY FORM  
Participant  Initial s                            ID               Date:             /               / 
                         Month         Day            Year  
 
 
Participant Off Study  
 
Date participant went Off Study :             /               / 
                                       Month         Day            Year  
 
INDICATE OFF STUDY REASON:  
  Study Activities Completed  
  Side effects of study intervention (complete applicable SAE form or AE Tracking Log)  
  Death   
  Participant  lost to follow -up* (provide comments below)  
   Participant  refused follow -up* (provide comments be low) 
   Other* (provide comments below)  
  Participant  withdrew (complete Early Withdrawal section below)  
 
Was treatment unblinded? 1 Yes    2 No    3 Not Applicable  
 
Early  Withdrawal  
 
Last Visit Completed:         Early Withdrawal form not completed
 
  Screening Visit  
  Visit 1   
  Visit 3 
  Visit 4  
  Visit 6 
  Visit 7    
        Visit 2                                              Visit 5 
Indicate the primary  reason the participant has withdrawn from the study (select only one):  
  Participant  deemed elig ible but declined participation  
  Participant  deemed inappropriate for study participation by the PI  
  Participant was determined to be ineligible after enrollment* (provide comments  
below)          
  Ident ification of disease/condition after enrollment that warrants withdrawal*  
   Unable to continue due to personal constraints*  
  Side effects of study intervention * (complete UWI -02-007 Adverse Event Tracking 
Log) 
  Other *                                           
 
80 
 *Additional explanation required:  
              
             
  
 
 
FORM COMPLETED BY :             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 APPENDIX S : TELEPHONE RECRUITMENT SCRIPT  
 
Hello, my name is _________.  Are you contacting me in regards to the non -invasive brain 
stimulation study?  
 
If ‘No’, redirect them as necessary)  
(If ‘Yes’, proceed)  
Do you have time now to hear about the study, answer a few screening questions, and schedule 
your first visit?  
 
(If ‘No’, ask for a good time to call back)  
(If ‘Yes’, proceed)  
 
Great! This study is looking at abnormal rhythms of brain activity in Major Depressive Disorder 
(and how they) respond to very weak applied electric currents. Findings from this study will help 
the development of treatments for the symptoms of depression.  In the study, a very weak electric 
current will be applied to your scalp. Some people report a mild tingling because of this 
stimulation, but no other side effects have been found. It is not a sh ock and should cause no pain.  
 
Participation in this study includes one to eight sessions, with one session being an initial 
information session, then 5 stimulation sessions, followed by a 2 and 4 week follow up session. 
The stimulation sessions need to b e over a consecutive week. You will be compensated for each 
hour of your time spent participating in the study, with a $20 completion bonus for finishing the 
study. Therefore, the maximum compensation for this study is $280 for completing all of the 
sessio ns. Are you still interested in participating?  
 
(If ‘No’, thank them for their time)  
(If ‘Yes’, proceed)  
 
Great! In order to make sure you’re eligible for the study, I need to ask you a few questions. 
Please answer yes or no. You do not need to provide any  further details.  
(If the answer given is not the same as the answer shown, thank the individual for his or her 
interest and say unfortunately, they do not qualify for the current study)  
 
 Are you 18 years old or older?  (Yes)  
 Have you ever, or are you cur rently being treated for a neurological condition (i.e. 
epilepsy, migraines, etc)? (No)  
 Are you currently taking medication for the treatment of depression or any other 
psychiatric  
illness? (No)  
o Have you ever taken medication for a mood disorder?  
o If yes, has it been at least 6 months since then?  
 How long have you been depressed?  
 
 What steps have you taken to treat this depression?  
 
82 
  
 
 Have you ever had brain surgery? (No)  
 Do you have any brain devices or implants, including a cochlear implant or aneurysm 
clip? (No)  
 Have you ever been diagnosed with a traumatic brain injury? (No)  
 For females only, is there a chance you may be pregnant? (No)  
 
Follow -up Questions  
 Have you been diagnosed with Major Depressive Disorder by a professional (i.e. a 
psychiatrist or ot her licensed clinician)?  
 Have you ever been hospitalized?  
o If yes, was it in anyway related to a mood disorder or psychiatric condition?  
o If yes, when did this occur?  
 Do you wear glasses/contact lenses?  
o Could you bring your contact lenses for the study visi ts instead of wearing your 
glasses?  
 
(If answered according to all indicated responses, continue)  
 
You are eligible for participation in the first session of the study. At the first session we will 
determine your eligibility for the remainder of the sessio ns.  I’d like to schedule your first 
session now. It will last approximately 3 hours. All testing will be conducted at either UNC 
Hospital or the NCPRC in Raleigh.  (Specify time).  
 
(Schedule a time for first session)  
 
I will send you an email or letter by  mail, depending on your preference,  confirming this time, 
and providing directions on how to find the specific location of you session. We will also send 
you an email, if you chose this form of communication to confirm your appointment 24 hours 
beforehan d. Please respond to this email so we know you are still coming. If you have any 
questions before then, please don’t hesitate to contact us at this phone number or at 
Courtney_lugo@med.unc.edu   
 
Thank you fo r your time.  
 
 
 
 
 